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Abstract
A necessary step in the retroviral lifecycle is integration, the covalent insertion of the viral cDNA into the
genome of the infected cell. This means that retroviruses, for example HIV, establish life-long infection. It also
means that retroviruses are used as gene-delivery vectors to treat genetic diseases. Integration events are
distributed non-randomly in the genome of the infected cell, with characteristic genus-specific preferences. In
this dissertation, we focus on the lentiviral class of retroviruses, and explore two aspects of their integration:
the means by which integration is targeted to its favored sites, and the consequences of integration at these
sites for the host cell. The host protein LEDGF/p75 has been shown to interact with lentiviral integrases and
contribute to their preference for integration in genes. We sought to establish the extent to which integration
site selection is determined by LEDGF/p75 tethering. We first asked whether LEDGF/p75 was an essential
integration tether, by analyzing integration site distribution in cells stringently depleted for LEDGF/p75. We
found that LEDGF/p75 is responsible for much of the lentiviral integration preference, though probably not
all. Secondly, we asked whether LEDGF/p75 tethering is sufficient to determine the genomic distribution of
lentiviral integration. We used a fusion of LEDGF/p75’s integrase-binding domain and the heterochromatin-
binding protein CBX1 to show that lentiviral integration could be retargeted away from its usual distribution
and into CBX1-bound regions. These results underline LEDGF/p75’s central role in lentiviral integration, and
the potential for manipulating its interaction with integrase. The effect of retroviral integration on the host cell
is of particular relevance in gene therapy, where insertional activation of proto-oncogenes in patients is a
serious concern. We present data on the genomic integration site distribution of a lentiviral vector for the
correction of β-thalassemia in mice. While use of the same vector in a human patient led to clonal outgrowth,
we report no evidence of insertional activation in the mouse model, but instead the suggestion that integration
in genes may impart a growth disadvantage. This argues for the safety of lentiviral vectors, but raises questions
about their effect on host gene expression.
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ABSTRACT 
 
LENTIVIRAL INTEGRATION SITE TARGETING: HOST DETERMINANTS 
AND CONSEQUENCES 
Keshet Ronen 
Advisor: Frederic D. Bushman 
 
A necessary step in the retroviral lifecycle is integration, the covalent insertion 
of the viral cDNA into the genome of the infected cell.  This means that retroviruses, 
for example HIV, establish life-long infection.  It also means that retroviruses are 
used as gene-delivery vectors to treat genetic diseases.  Integration events are 
distributed non-randomly in the genome of the infected cell, with characteristic 
genus-specific preferences.  This dissertation focuses on the lentiviral class of 
retroviruses, and explores two aspects of their integration: the means by which 
integration is targeted to its favored sites, and the consequences of integration at these 
sites for the host cell.  The host protein LEDGF/p75 has been shown to interact with 
lentiviral integrases and contribute to their preference for integration in genes.  We 
sought to establish the extent to which integration site selection is determined by 
LEDGF/p75 tethering.  We first asked whether LEDGF/p75 was an essential 
integration tether, by analyzing integration site distribution in cells stringently 
depleted for LEDGF/p75.  We found that LEDGF/p75 is responsible for much of the 
lentiviral integration preference, though probably not all.  Secondly, we asked 
 vi 
whether LEDGF/p75 tethering is sufficient to determine the genomic distribution of 
lentiviral integration. We used a fusion of LEDGF/p75’s integrase-binding domain 
and the heterochromatin-binding protein CBX1 to show that lentiviral integration 
could be retargeted away from its usual distribution and into CBX1-bound regions.  
These results underline LEDGF/p75’s central role in lentiviral integration, and the 
potential for manipulating its interaction with integrase.  The effect of retroviral 
integration on the host cell is of particular relevance in gene therapy, where 
insertional activation of proto-oncogenes in patients is a serious concern.  We present 
data on the genomic integration site distribution of a lentiviral vector for the 
correction of β-thalassemia in mice.  While use of the same vector in a human patient 
led to clonal outgrowth, we report no evidence of insertional activation in the mouse 
model, but instead the suggestion that integration in genes may impart a growth 
disadvantage.  This argues for the safety of lentiviral vectors, but raises questions 
about their effect on host gene expression. 
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CHAPTER 1 – INTRODUCTION 
 
1.1 Properties and lifecycle of the Retroviridae 
Retroviruses are a diverse class of spherical, enveloped RNA viruses 
belonging to the family Retroviridae.  Retroviral virions are 80-150nm in diameter 
and composed of two copies of a single-stranded positive-sense RNA genome, 
surrounded by a protein core, enveloped in a lipid bilayer of host cell origin studded 
with viral glycoproteins.  Two steps in the viral lifecycle define the group: reverse 
transcription of the single-stranded RNA genome into double-stranded DNA, and 
subsequent integration of this DNA copy of the genome into the genome of the 
infected cell. 
A schematic of the virion structure and lifecycle of retroviruses is illustrated 
in Figure 1-1.  Following interaction of viral envelope proteins with a cellular 
receptor, membrane fusion takes place, either at the surface of the host cell or after 
endocytosis, depending on the retrovirus [1-4] and the viral core is released into the 
cytoplasm [5].  The core is made up of, in addition to the RNA genome dimer, the 
structural proteins matrix (MA), capsid (CA) and nucleocapsid (NC), and the 
replication enzymes protease (PR), reverse transcriptase (RT) and integrase (IN).  
Accessory proteins may also be present depending on the virus, as well as other 
molecules from the host cell [6-8].  After entry, the core undergoes a poorly 
characterized change in core composition known as uncoating [9].  Reverse 
transcription, mediated by virion-packaged RT, takes place [10] and the core moves 
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lifecycle.  Adapted from Greene and Peterlin [9].
A
B
SU
TM}
RNA
genome
cDNA 
genome
Host cell 
genome
2
through the cytoplasm to the nucleus by interactions with actin microfilaments [11] 
and microtubules [12].  Further changes in core structure following reverse 
transcription generate the pre-integration complex (PIC), made up of the reverse 
transcribed genome, associated with a number of viral and cellular proteins [10, 13-
15].  When the PIC reaches the host chromatin, the viral cDNA is integrated into the 
host genome by IN [16-20].  Integrated viral genomes, known as proviruses, then 
function akin to endogenous host genes, transcribed and translated by host machinery 
to generate new viral RNA genomes and virion proteins. 
The genomes of retroviruses contain four essential genes encoding virion 
proteins: Gag, Pol, Pro and Env.  Pro (PR) is the viral protease, and post-
translationally cleaves polyproteins Gag and Pol during virion maturation.  Gag is 
cleaved into the structural proteins MA, CA and NC, and in some cases additional 
proteins.  Pol is cleaved into viral enzymes RT and IN (and in some viruses, PR).  
Env is cleaved into the surface glycoprotein (SU) and transmembrane protein (TM), 
which decorate the viral envelope (Env is cleaved by a cellular protease in the Golgi 
rather than the viral PR). Some retroviruses, known as complex retroviruses, 
additionally encode accessory proteins, which generally have roles in regulating viral 
gene expression, combating host defenses, or increasing infectivity [6].  All retroviral 
genomes contain regulatory regions at their 5’ and 3’ ends made up of U5 and U3 
respectively, each flanked by a direct repeat, R. Following reverse transcription, these 
untranslated elements become rearranged and duplicated, so the cDNA and provirus 
contain a directly repeated sequence at each end, a long terminal repeat (LTR), in the 
3
configuration U3-R-U5 [21].  The arrangement of the reverse-transcribed genome of 
HIV is shown in Figure 1-2A.  The LTRs contain sequence elements required for IN 
function [22-24] and viral gene expression.  U3 contains promoter and enhancer 
elements, including host transcription factor binding sites [25].  Sequences in R or U3 
in the 3’ LTR form the polyadenylation signal [26]. 
Virion proteins are translated as Gag, Gag-Pol, Env and Pro (Pro is expressed 
as part of Gag or Pol, or individually depending on the virus).  Gag, Gag-Pol and Pro 
associate with the nascent viral genome to assemble the virion core.  Env is targeted 
to the cell membrane, from where new virions bud.  Budding envelops the core in 
cellular lipid membrane studded with the Env protein.  Following budding, the virion 
polyproteins are processed by the viral protease, leading to structural changes to the 
core known as maturation. 
The family Retroviridae is divided into two sub-families, the 
orthoretrovirinae and the spumaretrovirinae.  The orthoretrovirinae have been better 
studied, since several members of the family cause disease in animal hosts.  The 
orthoretrovirinae are classified into six genera on the basis of sequence similarity.  
The genera and example members of each genus are listed in Table 1-1.  The 
lentiviruses, which will be the topic of this dissertation, are a family of complex 
retroviruses named for their ‘slowness’.  They infect a range of mammalian hosts, and 
infection is characterized by long incubation periods, persistent viral replication and 
the destruction of hematologic or immunologic cells [6].  This genus contains HIV, 
SIV and FIV, which cause immunodeficiency in human, simian and feline hosts 
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Table 1-1.  Retroviral genera and example members. Adapted from Coffin et al. 
[6]. 
Genus Type species Other examples Notes
Alpharetrovirus
Avian leukosis virus 
(ALV)
Rous sarcoma virus (RSV)
Simple genome; associated with 
anemia, sarcoma and other tumors 
in avian hosts
Betaretrovirus
Mouse mammary 
tumor virus (MMTV)
Jaagsiekte sheep retrovirus (JSRV)
Simple genome; associated with 
cancer in mammalian hosts
Gammaretrovirus
Murine leukemia virus 
(MLV)
Feline leukemia virus (FeLV),  
Xenotropic murine leukemia virus-
related virus (XMRV)
Simple genome; associated with 
cancer in mammalian hosts
Deltaretrovirus
Bovine leukemia virus 
(BLV)
Human T-lymphotropic virus (HTLV)
Complex genome; associated with 
leukemia and lymphoma in 
mammalian hosts
Epsilonretrovirus
Walleye dermal 
sarcoma virus (WDSV)
Complex genome; Infect fish
Lentivirus
Human 
immunodeficiency 
virus (HIV)
Simian immunodeficiency virus (SIV), 
Feline immunodeficiency virus (FIV), 
Equine infectious anemia virus (EIAV)
Complex genome; slow, chronic 
viral replication in mammalian 
hosts; can infect non-dividing cells
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respectively, and EIAV, which causes anemia in horses.  A distinguishing feature of 
lentiviruses is their ability to infect non-dividing cells, engendering great interest in 
steps of their lifecycle leading up to their interaction with the host genome [27], and 
enabling their use as gene delivery vectors in terminally differentiated cell types 
(discussed in section 1.9 of this chapter). 
1.2 Clinical relevance of lentiviruses 
The retrovirus of greatest clinical importance is arguably the complex 
lentivirus, human immunodeficiency virus (HIV), identified in 1983 as the causative 
agent of acquired immunodeficiency disorder syndrome (AIDS) [28, 29].  HIV is 
transmitted by direct sexual contact, contact with blood or blood products, and from 
mothers to infants intrapartum, peripartum or through breast-feeding [6].  Both cell-
free and cell-associated virus can play a role in transmission [30].  HIV infects 
immune cells expressing the receptor CD4, namely T-cells and macrophages.  
Primary infection is associated with an acute phase of mononucleosis-like illness, 
high viremia and low CD4+ T-cell count 3-6 weeks after transmission [6].   
Following acute infection, viral load drops and CD4+ count recovers, but over a 
period of several years, untreated infection results in a slow increase in viral load and 
decline in CD4+ T-cells.  This period of slow decline is known as clinical latency, 
and is asymptomatic.  Eventually, CD4+ T-cell numbers decline below a critical 
threshold, leading to AIDS: increased susceptibility to opportunistic infections, which 
ultimately lead to the patient’s death.  According to the World Health Organization, 
7
an estimated 33.4 million people are currently infected with HIV worldwide and 2 
million HIV-related deaths occurred in 2008 [31]. 
While an effective HIV vaccine remains elusive, pharmacological inhibitors 
of several steps of the HIV lifecycle have been developed and are used for the 
treatment of HIV.  Roughly 30 inhibitors have been developed and approved for use 
in patients, targeting the entry, reverse transcription, integration or maturation steps of 
the viral lifecyle.  These are typically administered as highly active antireroviral 
therapy (HAART), a cocktail of three drugs taken together to reduce the risk of 
development of resistance to any one drug.  While the drugs currently in use have 
made a remarkable impact on HIV mortality and morbidity, they must be taken 
indefinitely and patients frequently develop resistance to them [32, 33], necessitating 
periodic changes to the patient’s drug regimen. There therefore remains much interest 
in shedding light on the lifecycle of HIV and related lentiviruses, particularly 
interactions of the virus with host cell factors, to identify potential novel therapeutic 
targets. 
1.3 Integration 
This dissertation focuses on the integration step of the viral lifecycle.  The 
ability of retroviruses to integrate into the host genome is responsible for several of 
the most challenging aspects of HIV treatment and eradication.  Integration of the 
genome allows the establishment of latency, prevents complete elimination of viruses 
with antiretrovirals [34], and enables archiving of drug resistance mutations [35].  
The covalent insertion of viral sequence into the host genome has also contributed to 
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genome evolution: roughly 8% of the human genome, for example, is composed of 
retroviral sequences and it is thought that some of these elements have been co-opted 
for the benefit of the host cell [36].  Finally, as described in detail in section 1.7 of 
this chapter, the ability of retroviruses to integrate DNA between their LTRs into host 
DNA has enabled their use in gene therapy, but the possibility of this event disrupting 
host gene expression is also the cause of safety concerns. 
The integration reaction is illustrated in Figure 1-3.  It is composed of three 
main steps: processing of viral DNA ends, joining of viral to host DNA, and repair of 
gaps.  The viral enzyme integrase (IN) has been shown to be sufficient for the first 
two steps in vitro [19, 20, 37, 38].  IN removes two nucleotides from the 3’ termini of 
the viral DNA, leaving recessed 3’ hydroxyl groups [39, 40].  IN then catalyzes attack 
by these hydroxyl groups on phosphodiester bonds in the target DNA backbone [19, 
20, 41].  This leaves single-stranded gaps between the points of joining on the two 
strands, which are probably repaired by host DNA repair enzymes [42]. 
The integrase protein is proteolytically cleaved from the Gag-Pol precursor 
upon virion maturation.  IN is composed of three domains: the N-terminal zinc-
binding domain (amino acids 1-50), the catalytic core (amino acids 50-212), and the 
C-terminal DNA-binding domain (amino acids 212-288) [43].  Three conserved 
amino acids (D,DX35E, referred to as the catalytic triad) in the catalytic core domain 
(CCD) are required for catalysis [44-46].  The structure of the CCD is an RNase H-
like fold, conserved among members of the RNase H phosphotransferase enzyme 
family [45, 47, 48].  The catalytic triad is brought together in space, and coordinates 
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Figure 1-3. The integration reaction.  A. Reverse-transcribed viral DNA (bold lines) 
is associated with integrase (IN), probably as a tetramer (green circles), in the pre-
integration complex. B. Terminal cleavage.  IN removes 2bp from the 3’ ends of the 
viral DNA, exposing hydroxyl groups and leaving 5’ overhangs. C. Strand transfer. 
IN catalyzes nucleophilic attack by the two 3’ OH groups on the phosphate backbone 
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differs by retrovirus (eg. 5bp for HIV). D. The reaction intermediate contains 
unpaired gaps at each viral-host DNA junction. E. Gap repair. Host enzymes are 
thought to fill in the gaps. F. The integrated provirus is identical in sequence to the 
reverse transcribed genome, and is flanked by a repeat in the host genome resulting 
from gap repair (in the case of HIV, 5bp).  Adapted from Ciuffi and Bushman [189].
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two divalent metal cations [49-53].  The core is also thought to function in DNA 
binding [24, 54] and contribute to target DNA sequence preference in vitro [55, 56].  
The N- and C-terminal domains are thought to promote DNA binding and 
multimerization [57-63].  No crystal structure of full-length IN has been published 
yet, but two-domain structures show CCDs associated as dimers [64-67], leading to a 
model of IN function in vivo as a dimer of dimers [68]. 
In vivo, integration is carried out by the PIC, a nucleoprotein complex derived 
from the viral core [10, 13, 69].  PICs can be isolated from infected cells and carry 
out coordinate integration of both ends of endogenous cDNA into target DNA 
supplied in vitro [10, 70, 71].  HIV PICs have been shown to contain, as well as IN, 
the viral proteins MA, RT, NC and Vpr [15] but very little CA [14].  A number of 
host proteins have also been found to associate with purified IN or with the PIC, and 
the contribution of such host factors to integration is discussed below and is a focus 
of this dissertation. 
1.4 Host factors in integration 
Attempts to identify candidate integration cofactors have used a number of 
approaches.  One approach has been to search for host proteins that stimulate 
integration by pre-integration complexes.  It was observed that gel-filtration of PICs 
in the presence of high salt resulted in a loss of integrase activity, which could be 
restored by adding back cell extracts.  By fractionating such extracts a number of host 
factors have been identified, including the non-histone chromatin protein HMGA1 in 
HIV PICs [72] and the chromatin-associated protein BAF in HIV [73] and MLV PICs 
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[74].  However, further studies of HMGA1 suggested it is not strictly required in HIV 
infection [75] and the role of BAF in infection remains unclear [76, 77].  Another 
approach has been identifying IN binding partners by yeast-two-hybrid.  The 
SWI/SNF chromatin remodeling protein Ini1, was identified as interacting with HIV 
IN [78], though its role in infection now appears to be in assembly [79].  More 
recently, TNPO3/transportin-SR2 was identified by yeast-two-hybrid as interacting 
with HIV IN [80], and appears to be an essential nuclear import factor, though it may 
also function through CA binding [81].  Similarly, the transcriptional coactivator 
LEDGF/p75 was identified by its co-immunoprecipitation with IN overexpressed in 
human cells [82].  LEDGF/p75 appears to be an essential lentiviral integration tether 
and is discussed in detail below and in Chapters 2 and 3 of this dissertation.  Most 
recently, genome-wide siRNA screens [83-85] have identified hundreds of candidate 
host factors necessary for HIV infection.  Potential roles of some of these factors in 
integration targeting are discussed in Chapter 5 of this dissertation. 
1.5 Genomic distribution of integration sites 
Early studies of integration in vitro suggested any DNA sequence could serve 
as a target for integration by purified IN or PICs.  Relatively weak local sequence 
preference [86-89], and a preference for distorted nucleosome-associated DNA [86, 
90-92] were observed.  The advent of genome sequencing enabled genome-wide 
studies of integration in cells, which have shown clear biases in the distribution of 
retroviral integration sites with respect to various genomic features [93-95].  Indeed 
different genera of retroviruses show different integration site preferences.  In a 
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number of cell types, HIV [93, 96-98] and other lentiviruses [99, 100] favor 
transcription units as integration sites, particularly active genes.  In contrast, 
gammaretroviruses such as MLV and XMRV show a preference for CpG islands and 
gene 5’ ends [95, 101], while alpharetroviruses such as ASLV, betaretroviruses such 
as MMTV and deltaretroviruses such as HTLV show relatively random integration 
patterns, with weak or no favoring of transcription units [94, 96, 102, 103]. 
The weak sequence preferences demonstrated by retroviral integrases do not 
fully account for the genomic distribution of integration sites [104].  Hypotheses that 
have been proposed to explain integration site targeting by retroviruses center around 
the ideas of chromatin accessibility or tethering.  Since much of the DNA in 
mammalian cells is tightly wrapped into higher order chromatin structures, and these 
structures change with transcriptional status and cell cycle phase, it may be that 
integration can only occur in regions that are in an exposed conformation.  The bias 
of MLV integration toward DNase I hypersensitive sites [105, 106] and of HIV away 
from alphoid repeats located in pericentric heterochromatin [89] lend some support to 
this idea.  However, the distinct patterns of different retroviruses in the same cell 
types are suggestive of virus-specific tethers, rather than simple accessibility. 
Consistent with the tracking of integration site preferences with retroviral 
genus, viral elements have been shown to determine integration site distributions.  In 
a study of chimeric HIV viruses bearing MLV IN, Gag or both, viruses containing 
MLV IN were found to integrate with an MLV-like distribution, with further 
influence of Gag when both MLV proteins were present [107].  The idea currently 
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favored in the field is therefore that retroviral PICs are targeted to particular regions 
of the host chromatin through interactions between viral and host proteins.  Tethering 
interactions are well documented in yeast retrotransposons, which are closely related 
to retroviruses [108, 109], and artificial fusions of HIV integrase to sequence-specific 
DNA-binding domains have been shown to direct integration to their recognition sites 
[110, 111].  IN, and other viral proteins identified as determining integration site 
preference [107] are obvious candidate binding partners for cellular tethering factors, 
though any viral component of the PIC described above could potentially play a role.   
1.6 LEDGF/p75 in lentiviral integration 
LEDGF/p75 is a ubiquitously expressed nuclear protein now widely accepted 
as a cofactor for lentiviral integration.  Interest in LEDGF/p75 in the HIV field began 
when it was found to interact with overexpressed HIV IN in the nucleus [82] and was 
identified as an IN binder by yeast-two-hybrid [112].  The protein was identified as 
p75, one of two splice variants from the PSIP1/LEDGF gene, reported to be a 
transcriptional coactivator that co-purified with the general transcription factor PC4 
[113].  The cellular function of LEDGF/p75 remains unclear.  In its initial isolation 
with PC4, it was shown to have weak transcriptional coactivator activity, though the 
p52 splice variant was more active.  Around the same time, the protein was also 
isolated from lens epithelium cells [114], and given the name Lens Epithelium 
Derived Growth Factor.  It has been implicated in cellular stress responses [115, 116] 
including apoptosis [117] and tumor angiogenesis [118], and it is disrupted in 
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chromosomal translocations associated with acute and chronic myeloid leukemias 
[119, 120]. 
  Mice lacking LEDGF/p75 expression have been generated, either by gene 
trap disruption [121] or knockout [122].  The mice are viable, showing some perinatal 
death due to problems feeding, and a range of phenotypic abnormalities in adulthood, 
including low fertility and homeotic defects, but normal lens epithelia.  Murine 
embryonic fibroblasts (MEFs) derived from these mice, as well as human cell lines 
stably knocked down for LEDGF/p75, grow normally and were used in the 
experiments described in later chapters. 
Figure 1-4 illustrates the domain structure of LEDGF/p75.  At its N-terminus 
(amino acids 1-325) is a PWWP domain, a nuclear-localization signal, two AT-hook 
motifs and three charged regions, which have all been implicated in chromatin 
binding [123-125].  The PWWP domain (named for its Pro-Trp-Trp-Pro motif) is 
found in a number of chromatin-binding proteins, and is thought to be a member of 
the Tudor domain Royal family [126-128].  LEDGF/p75 shows sequence-non-
specific DNA binding [124], but the relative contributions of binding to DNA and 
protein in chromatin remain unclear. 
p75’s C-terminus contains a domain that binds lentiviral integrases, but not 
the IN of other classes of retroviruses [123, 129-131], named the integrase-binding 
domain (IBD, amino acids 347-429).  On IN, the CCD is minimally sufficient for the 
interaction, but is bolstered by contacts with the NTD [112, 132].  Crystal structures 
have been solved of the LEDGF/p75 IBD bounds to the HIV IN CCD and NTD, and 
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Figure 1-4.  LEDGF/p75 domain structure and interactions.  PWWP, PWWP 
domain; CR, charged region; NLS nuclear localization signal; AT, AT-hooks; IBD, 
integrase-binding domain.  Arrows represent interaction of various domains with 
chromatin (? represents unknown chromatin ligands, the helix represents DNA) or 
integrase, represented as a tetramer bound to viral cDNA.  Domain structure adapted 
from Gijsbers et al. [190].
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show each LEDGF/p75 IBD interacting with two CCD interfaces and one NTD [68, 
133].  A number of cellular proteins have been also been shown to interact with 
LEDGF/p75’s IBD: JPO2, a c-myc-binding protein [134]; pogZ, a domesticated 
transposase with sequence similarity to retroviral IN [135]; and menin, an adaptor 
protein associated with the histone-methyltransferase MLL [136]. 
Consistent with its modular structure – the N-terminus binding chromatin and 
the C-terminus binding integrase – LEDGF/p75 has been shown to function as a 
molecular tether, recruiting IN (and its other binding partners) to chromatin.  When 
IN was overexpressed in wild-type cells it colocalized with LEDGF/p75 and 
chromatin [82, 129, 132].  Depletion of LEDGF/p75 by RNAi or mutations that 
abrogated LEDGF/p75’s interaction with IN or chromatin led to loss of IN nuclear 
localization [112, 129, 132, 137, 138].  This led to early proposals that LEDGF/p75 
was responsible for nuclear import of IN [132].  However, subsequent studies with 
NLS-deleted LEDGF/p75 showed that IN could achieve nuclear localization in 
dividing cells due to nuclear-cytosolic mixing during division [123].  Whether 
LEDGF/p75 effects transport of IN across the nuclear membrane or acts to retain it on 
chromatin after import is not fully determined, though experiments with whole virus 
favor the latter model (see below). 
LEDGF/p75 enhances IN activity in vitro [82].  This stimulatory activity 
requires integrase binding and DNA binding [124, 131]. This may be a biologically 
important activity of LEDGF/p75, but caution is warranted in this interpretation 
because many nonspecific DNA binding proteins display this activity in vitro.  
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LEDGF/p75 also enhances the solubility of IN [130], and protects it from 
proteasomal degradation, independently of its chromatin-tethering function [139, 
140]. 
In addition to the above evidence of LEDGF/p75’s role in binding, trafficking 
and stimulation of purified or overexpressed IN, its role in cellular infection has also 
been demonstrated.  It has been suggested to be a component of functional PICs [129] 
and partly reconstitute the activity of salt-disrupted PICs [141].  Early studies of 
LEDGF/p75 knockdown reported little [142, 143] or no effect [129, 141, 144] on the 
level of HIV infectivity.  However, a role as an integration cofactor was supported by 
the finding that a virus bearing an IN mutation that disrupted LEDGF/p75 binding 
while preserving catalytic activity exhibited a severe infection block [112], though 
effects on other infection steps were hard to rule out.  Similarly, overexpression of the 
IBD was reported to act as a dominant negative and inhibit infection at the step of 
integration [138], arguing that LEDGF/p75 had a role in HIV integration in vivo. 
Based on this model, it seemed probable that LEDGF/p75 could be a 
determinant of the genomic distribution of lentiviral integration events.  Indeed, a role 
for LEDGF/p75 in integration site selection was demonstrated in human cell lines 
stably expressing siRNAs against LEDGF/p75 [144].  Knockdown led to a 
significant, but partial, reduction in the frequency of integration in transcription units, 
specifically in LEDGF-responsive genes (as determined by transcriptional profiling 
of knockdown cells) and A/T-rich regions of the genome, hypothesized to be bound 
by LEDGF by virtue of its AT-hook motifs. 
18
The absence of an infectivity defect in knockdown cells generated by a variety 
of labs was ultimately argued to be due to residual chromatin-associated LEDGF/p75 
expression.  Intensified knockdown cells were engineered by stable expression of 
lentiviral vectors containing LEDGF/p75 shRNA constructs [140].  In these cells, no 
residuum was detected and HIV infection was reduced 31-fold at the integration step 
of the viral lifecycle.  An increased accumulation of 2-LTR circles was noted, a 
species of viral cDNA known to be generated by nuclear NHEJ enzymes and thus 
taken as a measure of nuclear import [145, 146].  Rescue of the infection defect 
required both chromatin- and integrase-binding capabilities of LEDGF/p75.  The 
LEDGF/p75 status of the producer cell had no impact on HIV infectivity, arguing that 
LEDGF/p75 is not packaged into virions. 
At the time this dissertation research was started, integration site selection in 
intensified knockdown cells had not been studied.  Additionally, a gene-trap 
LEDGF/p75 mouse model had been generated, in which lentiviral infection had not 
been studied.  This left open the possibility that the remaining targeting to 
transcription units observed by Ciuffi and colleagues [144] was due to the residual 
LEDGF/p75 expression in the cells used, and additionally provided us another model 
in which to verify the effect of LEDGF/p75 depletion on lentiviral infection.  It 
remained unclear: 
1. whether LEDGF/p75 was necessary for lentiviral integration site selection in full 
2. whether it cooperated with or was antagonized by other determinants 
3. whether it was sufficient to determine the sites of lentiviral integration. 
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Addressing these questions was therefore one goal of the work described in this 
dissertation.  In Chapter 2, we seek to determine the necessity of LEDGF/p75 by 
studying HIV and EIAV integration sites in intensified human knockdown cells and 
MEFs from a gene-trap-disrupted mouse model with undetectable LEDGF/p75 
expression.  In Chapter 3, we address the issue of sufficiency by using fusion proteins 
containing the LEDGF/p75 IBD and alternative chromatin binding domains to 
retarget lentiviral integration.  In Chapters 5 and 6, we consider other factors that may 
contribute to integration site selection. 
   Another part of this dissertation concerns integration in gene therapy, and we 
now turn to that topic. 
1.7 Use of retroviral vectors for gene therapy 
The ability of retroviruses to covalently integrate their genetic material into 
the host genome has made them attractive vehicles for the delivery of corrective 
genes in patients suffering from genetic diseases.  Generation of a retroviral gene 
delivery vector essentially involves replacing the viral genes gag, pol and env with 
the host transgene.  This is illustrated in Figure 1-2B.  The resulting transfer vector, 
bearing the transgene, viral packaging signal and LTR sequences, functions like a 
retroviral genome.  The packaging proteins (Gag, Gag-Pol and Env) must be provided 
in trans, since they are absent from the ‘genome’ that bears the transgene.  Cells 
therefore express, transiently or stably, the transfer vector, a Gag-Pol vector and an 
envelope vector, and produce packaged virions [147, 148].  These virions are used to 
transduce patient cells, the transfer vector undergoes reverse transcription and 
20
integration, and the corrective gene is stably expressed. Retroviruses have a coding 
capacity of around 7-7.5kb, can be manufactured at relatively high titers, and have a 
fairly high transduction efficiency, making them practical transfer vectors [149-151]. 
Gammaretroviral vectors (based on MLV) were the first to be developed, and 
remain the most widely used, with 333 clinical trials completed or in progress 
worldwide as of December 2009 [152]. A major limitation of gammaretroviral 
vectors is their inability to infect non-dividing cells.  In an effort to expand the range 
of disorders to which gene therapy could be applied, lentiviral vectors, which are able 
to infect non-dividing cells, have recently increased in popularity, with 24 trials 
currently completed or on-going. 
 The greatest success has been in the development of techniques for treatment 
of hematological disorders such as SCID-X1, ADA-SCID and CGD, ALD and β-
thalassemia.  In these protocols, bone marrow is harvested from the patient and 
transduced ex vixo.  Transduced cells are then transplanted back into the patient 
following myeloablation, and gene-corrected stem cells reconstitute the bone marrow 
[151]. 
The work of many labs has enhanced the design of transfer vectors to improve 
transgene expression and prevent silencing.  Some of these elements are illustrated in 
Figure 1-2B.  Transduction efficiency is improved by the incorporation of sequence 
elements to enhance RT and possibly PIC nuclear import, for example a polypurine 
tract in the cDNA, the cPPT [153].  Replacement of the viral LTR promoter with an 
alternative cellular promoter can enhance transcription initiation, target certain cell 
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types and enhance long-term expression [147].  Transcript nuclear export can be 
maximized by incorporating an intron or a post-transcriptional regulatory element 
such as the WPRE from Woodchuck Hepatitis virus [154, 155].  The risk of transgene 
silencing by DNA methylation is reduced by incorporating insulator elements that 
prevent the spread of epigenetic modifications from surrounding DNA [147, 148].  A 
range of envelope glycoproteins are now also in use, enabling some degree of tissue-
specific targeting [156]. 
One safety concern over the use of retroviral vectors has been the potential for 
reconstitution of an infectious retrovirus by recombination of transfer and packaging 
vectors.  This has been dealt with by separating gag-pol and env sequences onto two 
separate packaging plasmids that do not contain overlapping viral sequence elements, 
reducing the probability of recombination during vector production [157].  Another 
safety issue is the possibility of insertional activation.  This is discussed in detail 
below, and remains a serious concern, despite various modifications to vector design 
intended to mitigate it. 
1.8 Insertional activation 
Since their discovery, retroviruses have been implicated in carcinogenesis 
[158, 159].  Indeed studies of tumor-associated retroviruses have contributed to our 
understanding of the development of cancer [6].  Retroviruses can exert oncogenic 
effects by encoding an oncogene, either a captured cellular gene [159-161] or a 
modified viral factor with oncogenic properties [162].  Alternatively, retroviruses 
lacking an encoded oncogene can alter the expression of a host growth control gene 
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close to the site of proviral integration by insertional activation. 
Insertional activation can be caused by a number of mechanisms [6].  One is 
upregulation of transcription of an oncogene by retroviral promoter or enhancer 
sequences inserted a short distance upstream of the gene.  Alternatively, proviruses 
may integrate within a gene, resulting in transcriptional readthrough, forming a 
hybrid transcript of viral and host sequence.  This hybrid may act as an aberrantly 
active growth factor, for example encode a constitutively active oncogene missing a 
regulatory domain.  Finally, an integrated provirus may separate a growth-control 
gene from non-coding regions that modulate its expression.  Tumors arising by 
insertional activation usually have a long latency – assuming the altered locus has a 
dominant phenotype, the initial integration event may impart a growth advantage on 
the cell, but additional mutations (second and third ‘hits’) will likely be required for a 
tumor to develop. Rarely, retroviruses can promote transformation by inactivating a 
tumor suppressor gene, though in this case the other allele must be inactivated as 
well. 
In a number of clinical trials of retroviral vectors, insertional activation has 
resulted in adverse events.  In the SCID-X1 trial, for example, 5 of 19 children treated 
with a gammaretroviral vector containing the common cytokine receptor γc chain 
went on to develop leukemia [163-165].  Analysis of the genomic sites of vector 
integration can provide evidence of insertional activation and shed light on the 
mechanism of oncogenesis.  Integration events that alter the expression of cellular 
growth control genes would be expected to impart a growth advantage to the cells 
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harboring them.  Those cells would therefore accumulate in the treated individual, 
and be more frequently recovered upon random sampling of circulating cells and 
bone marrow.  Such analysis has been carried out for a number of gene therapy trials.  
In the SCID-X1 trial, for example, samples from patients who developed leukemia 
exhibited integration sites within or near the known growth-control genes LMO2, 
BMI1 and CCND2 in blast cells [164].  Clonal dominance was also observed in a trial 
of a gammaretroviral vector administered for the treatment of chronic granulomatous 
disease, which progressed to leukemia.  In this case, both patients developed a clonal 
expansion of myeloid cells bearing integration sites in MDS1/EVI1, PDRM16 or 
SETBP1 and myelodysplasia [166, 167]. 
The factors determining the incidence and consequences of insertional 
activation are not fully understood, but are likely a combination of vector regulatory 
elements, the nature of the transgene, the culture and transduction conditions 
employed and characteristics of the target cell [168].   
The contribution of cell-intrinsic factors to the incidence of insertional 
activation is relatively poorly characterized.  The self-renewal properties of the target 
cell likely affect the consequences of vector integration.  For example, Recchia and 
colleagues reported [169] that gammaretroviral transduction of terminally 
differentiated T-cells, though altering the expression of a large number of cellular 
genes, did not result in clonal skewing as long as 9 years post-transplantation.  
Similarly, Kustikova et al. reported that clonal dominance developed following 
gammaretroviral transduction of hematopoietic stem cell populations, but not more 
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lineage-restricted progenitors [170]. 
Likewise, the nature of the transgene and the nature of the disorder being 
treated is thought to affect the potential for insertional activation. For example, in the 
SCID-X1 trial, it is likely that the fact the γc chain was required for the survival of the 
targeted cells and that corrected cells expanded to fill an empty hematological 
compartment meant that transduced cells already had a growth advantage, increasing 
the selective forces driving clonal outgrowth [168]. 
The determinant of insertional activation viewed as the most straightforward 
to control is vector design.  One proposed approach to reducing the risk of gene 
therapy would be to target integration events to specific sites in the genome, chosen 
to lie far from growth-control genes to minimize the risk of insertional activation.  
This is not yet a practical approach, but some success has been achieved creating 
chimeric proteins to retarget integration.  Chapter 3 of this dissertation describes 
retargeting of lentiviral integration out of transcription units using such a LEDGF/p75 
fusion. 
In the absence of targeted integration, numerous vector design modifications 
have been proposed to reduce the vector’s impact on the expression of nearby genes.  
Notably, many of these features were not present in the vectors used in the clinical 
trials and resulting adverse events described above [166, 171]. Use of physiologic 
cellular promoters such as PGK or EF1α to drive transgene expression, rather than 
strong retroviral promoters, has been shown to reduce transactivation [172].  The 
inclusion of insulator elements in vectors, in addition to reducing transgene silencing, 
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reduces activation of neighboring genes by proviral promoter and enhancer elements 
[173, 174].  Deletion of U3, which contains the viral promoter sequence, from the 3’ 
LTR of the viral genome reduces transactivation of neighboring genes [175, 176].  
Studies of insertional activation with such vectors, termed ‘self-inactivating’ (SIN), 
have supported the idea that they are less genotoxic [172, 177], though there remain 
examples of tumor development with SIN vectors [173, 178].  Insertional activation 
by leaky vector transcription can be reduced by the incorporation of exogenous 
polyadenylation signals such as that of SV40 in addition to that in the 3’ U5 [179].  
Finally, lentiviral vectors have been proposed to be safer than gammaretroviral 
vectors, as discussed below.  
1.9 Lentiviral vectors 
Until 2008, only gammaretroviral vectors had been used in clinical trials of 
gene therapy, though lentiviral vectors have long been attractive due to their ability to 
transduce non-dividing cells.  Additionally, it was expected that lentiviral vectors 
might have a better safety profile.  Unlike gammaretroviruses, insertional oncogenesis 
is not a common feature of infection with lentiviruses, for example HIV.  Though it 
has been reported [180], none of the data to date is convincing.  It has also been 
posited that differences in integration site preferences between letiviruses and 
gammaretroviruses might impact their safety profiles [148, 181].  Gammaretroviral 
vectors show a strong propensity to integrate at promoters and gene 5’ ends [95], 
where transcriptional read-through from the viral LTR can lead to upregulation of the 
downstream gene [182].  Lentiviruses, on the other hand, favor integration in the 
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bodies of transcription units, avoiding regulatory 5’ regions [93, 94, 98].  Indeed, 
studies in tumor-prone mouse models [183, 184] and tissue culture systems [185] 
have reported less genotoxicity resulting from lentiviral than gammaretroviral 
transduction. 
Three clinical trials have been conducted using lentiviral vectors in humans, 
and have yielded mixed evidence regarding the consequences of integration.  The first 
trial involved delivery of an HIV env antisense payload to terminally differentiated T-
cells infected with HIV [186], and integration events in these patients showed no 
evidence of enrichment of sites in proto-oncogenes following transduction [187].  The 
second published trial, to treat ALD, involved delivery with a SIN vector containing 
the ABCD1 gene into hematopoietic stem cells [188].  Integration sites in these two 
patients also showed sustained polyclonality up to 24 months after transplantation, 
and clear clinical benefit was achieved.  Thirdly, one patient was treated for β-
thalassemia with a SIN lentiviral vector encoding β-globin (Cavazzana-Calvo et al., 
submitted), and again clinical benefit was achieved, though in this case a clonal 
expansion bearing a site within the proto-oncogene HMGA2 was observed. 
Given our limited understanding of the factors determining the consequences 
of retroviral gene therapy, the results of the human β-thalassemia trial raised 
questions about the possibility of SIN lentiviral vector integration near growth-control 
genes imparting a selective advantage and leading to preferential outgrowth of the 
target cell.  In Chapter 4, we present a study of the distribution of integration sites 
from the same lentiviral vector as was used in the human β-thalassemia trial, used to 
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treat a mouse model.  We sought to determine the generality of the finding in the 
human trial and contribute to our understanding of the consequences of integration 
with this vector for the infected cell. 
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CHAPTER 2 – THE ROLE OF PSIP1/LEDGF/p75 IN LENTIVIRAL 
INFECTIVITY AND INTEGRATION TARGETING 
 
The contents of this chapter have been published as part of: 
Marshall HM*, Ronen K*, Berry C, Llano M, Sutherland H, Saenz D, Bickmore 
W, Poeschla E, Bushman FD. (2007) Role of PSIP1/LEDGF/p75 in lentiviral 
infectivity and integration targeting. PLoS One. 2(12):e1340. 
*equal contribution 
 
2.1 Abstract 
To replicate, lentiviruses such as HIV must integrate DNA copies of their 
RNA genomes into host cell chromosomes.  Lentiviral integration is favored in active 
transcription units, which allows efficient viral gene expression after integration, but 
the mechanisms directing integration targeting are incompletely understood. A 
cellular protein, PSIP1/LEDGF/p75, binds tightly to the lentiviral-encoded integrase 
protein (IN), and has been reported to be important for HIV infectivity and integration 
targeting.  Here we report studies of lentiviral integration targeting in murine cells 
with homozygous gene trap mutations in the PSIP1/LEDGF/p75 locus.  Infections 
with vectors derived from HIV and equine infections anemia virus (EIAV) were 
compared. Integration acceptor sites were analyzed by DNA bar coding and 
pyrosequencing.  In PSIP1/LEDGF/p75-depleted murine embryonic firbroblasts, 
reductions were seen in lentiviral infectivity compared to controls. Reductions in 
integration in transcription units were seen, paralleling studies of human models and a 
different mutant mouse line.  Integration did not become random, however – 
integration in transcription units was still favored, though to a reduced degree.  New 
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trends also appeared, including favored integration near CpG islands.  In addition, we 
carried out a bioinformatic study of 15 HIV integration site data sets in different cell 
types, which showed that the frequency of integration in transcription units was 
correlated with the cell-type specific levels of PSIP1/LEDGF/p75 expression.   
2.2 Introduction 
 Early steps of retroviral replication involve reverse transcription to generate a 
DNA copy of the viral RNA genome, and integration, which results in the covalent 
connection of the viral DNA to host cell DNA (for reviews see [1, 2]).  The question 
of where retroviruses target DNA integration is central to understanding viral host 
interactions.  For the virus, selection of favorable sites for viral DNA integration 
assists efficient expression of the viral genome after integration [3-6].  For the host, 
viral DNA integration can either activate or inactivate gene transcription.  One 
consequence of integration can be insertional activation of oncogenes and 
transformation to malignant growth [1, 2, 7, 8].  Here we present data on the role of a 
host-cell encoded protein, PSIP1/LEDGF/p75, that guides integration site selection 
by lentiviruses, the viral genus including HIV (henceforth we use "LEDGF/p75" 
because this name is widely used in the HIV field). 
 LEDGF/p75 first came to the attention of the retrovirus field when it was 
identified in affinity-based screens for its tight binding to HIV IN [9-11].  
LEDGF/p75 tethers ectopically-expressed HIV IN to chromatin [9, 10, 12, 13], 
through specific binding domains [14-17], and also protects IN from proteasomal 
degradation [18].  LEDGF/p75 binding is specific for lentiviral IN proteins (e. g. 
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those of HIV, SIV, FIV, and EIAV) [12, 19, 20], which makes it appealing as a 
candidate tethering factor since all lentiviruses tested (HIV, SIV, FIV, and EIAV) 
show favored integration in active transcription units [5, 21-32].  The crystal structure 
of the catalytic domain of HIV IN (residues 50-212) bound to the integrase binding 
domain (IBD) was solved, which showed that a pair of LEDGF/p75-IBD molecules 
could bind at symmetry-related positions at the interface of the IN catalytic domain 
dimer [33, 34]. 
Early attempts to determine whether LEDGF/p75 was important for efficient 
HIV replication used RNAi knockdowns in human cells, which had either no effect or 
quantitatively modest effects on infection [12, 13, 35, 36].  This now appears to be 
because incomplete knockdowns left biologically significant amounts of protein 
present.  More recently, human SupT1 cells with intensified RNAi knockdowns 
showed infectivity drops of 30-fold by either HIV or another lentivirus, feline 
immunodeficiency virus (FIV), and combining this with dominant interfering proteins 
derived from the LEDGF/p75-IBD produced 560-fold inhibition of infection [37].  
These findings are supported by additional studies in human cell lines [35, 38, 39].   
 Early knockdowns of LEDGF/p75 were also analyzed for effects on targeting 
of HIV integration [40].  Knockdowns in three cell types were studied, and in each 
integration frequency within transcription units was reduced.  In addition, other 
effects were seen, including an increase in the content of G/C bases around sites of 
HIV integration in the knockdown cells.  These data supported the idea that 
LEDGF/p75 acted as a tethering factor, binding to both HIV and chromatin to direct 
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HIV integration into active genes.  In support of the tethering model, artificial fusion 
proteins in which the LEDGF/p75 IBD was fused to the sequence specific DNA 
binding domain of phage lambda repressor were shown to direct favored integration 
in vitro near repressor binding sites [24].  Also supporting the tethering idea, function 
of LEDGF/p75 in promoting HIV replication requires that both ends of the putative 
LEDGF/p75 tether be intact [37]. 
 However, key questions still remained on the role of LEDGF/p75.  In all the 
models studied, HIV continued to favor integration within active transcription units.  
This could either be because residual LEDGF/p75 remaining in the knockdown was 
sufficient for residual targeting activity, or because additional host cell factors also 
contribute independently to targeting HIV integration.  In an effort to address this 
issue, we studied mouse cells containing homozygous gene trap mutations at the 
LEDGF/p75 locus developed by Sutherland and coworkers [42].  Vectors derived 
from equine infectious anemia virus (EIAV) were used in many of the experiments, 
allowing effects on HIV and EIAV to be compared.  Studies of both lentiviruses 
provided strong evidence for the role of LEDGF/p75 in promoting efficient infection 
and targeting integration in transcription units.  Additionally, new integration 
preferences emerged in LEDGF/p75-depleted cells, and some targeting to 
transcription units persisted.  In data not shown, Heather Marshall in the lab 
conducted similar experiments with the human SupT1 T-cell line with intensified 
RNAi developed by Llano et al. [37], and obtained similar results, confirming that 
murine cells are an appropriate model for LEDGF/p75 function. 
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While our study was under way, Shun et al. prepared a mouse strain in which 
part of the LEDGF/p75 locus was flanked by Cre recombination sites [41], and the 
LEDGF/p75 exon was deleted by exposure to Cre recombinase.  Mouse embryonic 
fibroblasts were then studied for effects on infection with HIV reporter viruses.  In 
agreement with our studies, these cells showed a 20-fold reduction in infectivity by 
HIV, and also a reduction in integration frequency in transcription units that was 
stronger than that reported in human cell knockdowns by Ciuffi et al. [40].  The 
mouse cells also showed some new targeting features in the LEDGF/p75-depleted 
cells, including increased integration near CpG islands.   
In addition to these data on manipulated cell models, we also present 
additional bioinformatic studies of 15 published HIV integration site data sets in 
different cell types, which revealed a strong correlation between cell type specific 
LEDGF/p75 expression levels and the proportion of HIV integration sites in 
transcription units.  These data provide further support for the generality of 
LEDGF/p75 as a determinant of integration target site selection for lentiviruses, 
including in primary cells where LEDGF/p75 levels were not artificially reduced. 
2.3 Materials and Methods 
Cell lines 
MEFs were extracted from wild-type and knockout embryos at 13.5 dpc [60] 
and cultured in DMEM with 10% FBS, 50µg/ml gentamycin, 110µM beta-
mercaptoethanol, 1X non-essential amino acids, 100µM sodium pyruvate.  Primary 
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MEFs (prMEFs) were immortalized by the 3T3 protocol, by splitting cells every 3 
days to a density of 6X104 cells/ml [61].   
Viral particle production and infections 
 VSV-G pseudotyped HIV vector particles were produced by Lipofectamine 
transfection of 293T cells with p156RRLsin-PPTCMVGFPWPRE [62], the 
packaging construct pCMVdeltaR9 [63], and the vesicular stomatitis virus G-
producing pMD.G construct.  EIAV vector particles were likewise produced by 
transfection with p6.1G3CeGFPw (M. Patel and J. Olsen, University of North 
Carolina, Chapel Hill unpublished), the packaging construct pEV53B [64], and the 
vesicular stomatitis virus G-producing plasmid pVSVG into 293T cells.  Viral 
supernatant was harvested 38 hours after transfection, filtered through 0.22µm filters, 
concentrated by filtration through a Centricon, treated with DNase I, and stored 
frozen at -80°C.  HIV titer was quantified by p24 ELISA. 
 For HIV infection, cells were plated onto 6-well plates at a density of 3X105 
cells per well and each well infected with 1µg p24. For EIAV, cells were plated into 
24-well plates at a density of 4X104 cells per well, and each well infected with 100µl 
concentrated virus. Infections were performed overnight in the presence of 10µg/ml 
DEAE-dextran.  10 independent HIV infections and 5 EIAV infections were 
performed per genotype.  48 hours after infection, 90% of cells were harvested for 
integration site cloning and the remainder passaged for an additional 2 weeks to dilute 
unintegrated products of reverse transcription and used for QPCR analysis of 
integration efficiency.  
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Infectivity tests 
For quantitative PCR analysis, infected cells were passaged for 2 weeks 
following infection to dilute unintegrated products of reverse transcription, then 
genomic DNA was extracted using the Qiagen DNeasy tissue extraction kit.  QPCR 
using HIV late-RT primers and probe was carried out as described in [44] using 50ng 
genomic DNA as template.  For EIAV, primer and probe sequences are described in 
Table S1.  25ng of SupT1 genomic DNA was used as template, 50ng of MEF 
genomic DNA.  QPCR was performed using Applied Biosystems 2X FAST universal 
master mix and Applied Biosystems FAST PCR machine. 
Integration site amplification 
Integration sites were isolated and sequenced by ligation-mediated PCR 
essentially as described previously [46].  Genomic DNA was extracted from infected 
cells using the Qiagen DNeasy tissue extraction kit. Up to 2µg of DNA from each 
infection was digested overnight using MseI. This was followed by digestion to 
prevent amplification of internal viral fragments (from the 5’ LTR) and plasmid 
backbone with SacI and DpnI in the case of HIV, and XmaI and DpnI in the case of 
EIAV.  Linkers were then ligated onto digested products (oligonucleotide sequences 
listed below) and nested PCR performed from ligation products.  Nested PCR primers 
contained 4 or 8 nt barcode sequences between the sequencing primer and LTR-
binding portions.  These enabled pooling of all PCR products into one sequencing 
reaction and subsequent separation of sequences by decoding the barcodes.  
Amplification products were gel-purified and sent to the Interdisciplinary Center for 
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Biotechnology Research at the University of Florida and the Virginia Bioinformatics 
Institute Core Laboratory Facility for pyrosequencing.  Sequences have been 
deposited in the NCBI database, under accession numbers GS773309-GS815944. 
Oligos used 
Bioinformatic analysis. 
 Integration sites were judged to be authentic if the sequences had a best unique 
hit when aligned to the murine (mm8 draft) using BLAT, and the alignment began 
within 3bp of the viral LTR end and had >98% sequence identity.  Detailed statistical 
methods are described in [55].  
 To control for possible biases in isolating integration sites due to restriction 
enzyme sequence distribution, three or ten matched random controls were 
computationally generated for each experimental integration site that were the same 
distance from the closest MseI restriction site as the experimental site. 
 Integration site counts in various genomic annotations were compared with 
matched random controls by the Fisher’s exact test.  Additionally, multiple regression 
Primer name Primer Sequence (5' ==> 3')
EIAV Primer PCR1 CCTGTCTCTAGTTTGTCTGTTCG 
EIAV nested PCR Forward gccttgccagcccgctcagxxxxAGTTTGTCTGTTCGAGATCCTACA*
HIV Primer PCR1 CTTAAGCCTCAATAAAGCTTGCCTTGAG
HIV nested PCR Forward gccttgccagcccgctcagxxxxAGACCCTTTTAGTCAGTGTGGAAAATC**
MseI Linker Primer for nested PCR gcctccctcgcgccatcagAGGGCTCCGCTTAAGGGAC***
MseI Linker Primer for PCR 1 GTAATACGACTCACTATAGGGC
MseI linker positive strand GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC
MseI linker negative strand [Phosp]-TAGTCCCTTAAGCGGAG-[AmC7-Q]****
EIAV Q-PCR forward CCG CAA TAA CCA CAT TTG TGA CGC
EIAV Q-PCR reverse GCA GAA TCT GAG TGC CCA ATT GTC AG
EIAV Q-PCR probe FAM-AGT TCC GCA TTG GTG ACG CGT TAA GT-Black_Hole_Quencher
HIV Q-PCR forward TGTGTGCCCGTCTGTTGTGT
HIV Q-PCR reverse GAGTCCTGCGTCGAGAGAGC
HIV Q-PCR probe FAM-CAGTGGCGCCCGAACAGGGA-TAMRA
*primer B - barcode - EIAV 3'LTR PRIMER (nested PCR)
**primer B - barcode - HIV 3'LTR PRIMER (nested PCR)
***primer A-MSEI LINKER PRIMER (for nested PCR)
**** modifications- [Phosp]=5' phosphate, [AmC7-Q]=3' amine
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models for integration intensity were applied, as described in [55].  
 For analysis of correlations with gene activity in murine integration sites 
(Figures 2-3 and 2-4), transcriptional profiling data from wild-type MEFs analyzed on 
the MGU74Av2 Affymetrix microarray were used.  Genes represented on the 
microarray were ranked by expression level and divided into 4 bins based on 
expression level.  Integration sites found within genes in each bin were counted as a 
proportion of sites found within genes in all bins.  
 For the analysis of relative gene activity in Figure 2-5, data from two types of 
Affymetrix chips were used (HU95A and HU133A).  Two probe sets querying 
LEDGF/p75 but not p52 were available on each chip (For HU95: 39243_s_at 
and 37622_r_at; for HU133: 209337_at and 205961_s_at).  To account for 
differences in the sensitivities arising from the different chip designs and probe sets, 
the values for each cell type were first ranked for each probe set and chip 
combination, then the ranked values pooled in the final data set. 
2.4 Results 
Efficiency of lentivirus infection in murine cells disrupted at LEDGF/p75 
Human cells stringently depleted for LEDGF/p75 [37] and murine embryonic 
fribroblasts (MEFs) from knockout mice [41] show a block in HIV infection.  We 
wanted to verify this block in lentiviral infection in MEFs containing the gene trap 
disruption of LEDGF/p75 reported by Sutherland and colleagues [42].  Because 
residual expression is sometimes detected in gene trap alleles, we used quantitative 
RT-PCR to determine the fraction of LEDGF/p75 messages disrupted by the gene 
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trap insertion. In samples from homozygous mutant (-/-) cells, amplification of 
correct LEDGF/p75 message was sporadically detected at high PCR cycle numbers, 
suggesting that rare correctly spliced messages were formed.  However, 
quantification of correct message formation using SyberGreen quantitative PCR 
showed expression of LEDGF/p75 to be below the limit of detection in the -/- cells, 
corresponding to a reduction of at least 32-fold compared to the wild type (+/+) cells 
(data not shown).  Sutherland and coworkers reported LEDGF/p75 protein to be 
undetectable [42]. 
We analyzed infection of MEFs isolated from embryos of +/+ and 
homozygous mutant -/- mice after infection with HIV and EIAV. Like HIV IN, EIAV 
IN is known to bind LEDGF/p75 [20], and EIAV is also known to integrate in active 
transcription units [31], so EIAV is a suitable model for analysis of the influence of 
LEDGF/p75 on lentivirus infection.  Integration was measured by infecting cells, 
maintaining the cells in culture for two weeks to allow loss of unintegrated DNA 
[44], then quantifying the viral DNA by TaqMan PCR.  HIV integration was reduced 
~five fold in the LEDGF/p75 -/- MEFs (Figure 2-1), and EIAV integration was 
reduced >50 fold.  Thus in the presence of a homozygous mutation of LEDGF/p75, 
lentiviral integration was strongly reduced but not eliminated.   
DNA bar coding and pyrosequencing to analyze integration site placement 
We used the pyrosequencing technology commercialized by 454 Life 
Sciences [45] to sequence genomic DNA flanking integrated proviruses.  Briefly, 
genomic DNA was isolated and cleaved with restriction enzymes.  DNA linkers were 
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Figure 2-1.  Efficiency of lentiviral infection in control and LEDGF/p75-
disrupted cells. Integration of HIV (A) and EIAV (B) was measured by quantitative 
PCR. +/+ control; -/- homozygous LEDGF/p75-disrupted.
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ligated onto the cleaved ends, then host-virus DNA junctions were amplified using 
one primer complementary to the linker and one complementary to the viral DNA 
end.  A second round of PCR was used to improve specificity and to add recognition 
sites for the 454 primers necessary for the emulsion PCR step preceding 
pyrosequencing [46].  Pooled DNAs were then sequenced. 
Use of DNA bar coding allowed multiple integration site populations to be 
studied in parallel [47-49].  The viral DNA primer used in the second round of 
amplification contained a short recognition sequence (4-8 bases) abutting the 454 
primer that was different for each sample tested.  These 4-8 bases are the first 
determined in pyrosequencing reads.  Thus use of bar coding allowed many samples 
to be pooled for sequence determination, then the reads could be sorted into 
individual experiments by bar code.  A total of 1757 unique integration site sequences 
from different virus and cell combinations were determined using this method (Table 
2-1). We analyzed integration sites in murine embryonic fibroblasts (MEFs) derived 
from the LEDGF/p75 homozygous gene trap (-/-) and control (+/+) mice [42] after 
infection with HIV and EIAV.  Cells that had been immortalized in culture (iMEF) 
were compared to primary MEFs (prMEFs).  For all the features discussed below the 
results were identical for iMEFs and prMEFs (data not shown), so the two data sets 
were pooled in what follows. 
Consensus sequences at lentiviral integration sites in murine cells disrupted at 
LEDGF/p75 
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Table 2-1.  Integration site data sets used in this study. 
Cell line
Description and LEDGF/p75 
status
Virus
Number of 
Integration 
Sites
Source of 
sequences 
analyzed
iMEF +/+
Murine embryonic fibroblasts 
from wild-type mice 
(immortalized)
HIV vector 574 This report
iMEF -/-
Murine embryonic fibroblasts 
from gene-trap mice 
(immortalized)
HIV vector 287 This report
prMEF +/+
Murine embryonic fibroblasts 
from wild-type mice (primary)
HIV vector 531 This report
prMEF -/-
Murine embryonic fibroblasts 
from gene-trap mice (primary)
HIV vector 209 This report
iMEF +/+
Murine embryonic fibroblasts 
from wild-type mice 
(immortalized)
EIAV vector 70 This report
iMEF -/-
Murine embryonic fibroblasts 
from gene-trap mice 
(immortalized)
EIAV vector 86 This report
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As a first step in the analysis, the favored target DNA sequences at the point 
of integration were compared in the presence and absence of LEDGF/p75.  
Alignment of target DNA sequences at integration sites has revealed weak inverted 
repeat consensus sequences [50-55], the symmetry arising because the favored 
sequence features at each of the two viral DNA ends are the same.  The presence of 
this consensus sequence can be a strong predictor of integration targeting specificity, 
particularly over short intervals [55].  For HIV, the favored consensus sequence, 
TDG↓GTWACCHA (where the arrow represents the site of integration) has been 
synthesized and shown to be a favored integration target site for HIV preintegration 
complexes in vitro [52]. EIAV has been reported to favor integration in an A/T rich 
palindromic consensus sequence [31] 
Integration site sequences were aligned to determine the consensus 
palindromic sequence at the point of integration, and results were compared for the 
+/+ and -/- MEFs for each virus (Figure 2-2).  In both cases, integration in the +/+ 
MEFs showed the weak consensus seen previously for HIV and EIAV.  No major 
differences were seen in the -/- MEFs, consistent with previous reports of 
LEDGF/p75 depletion [40, 41].   
HIV integration targeting in murine cells disrupted at LEDGF/p75 
Genome-wide studies of HIV integration targeting in murine cells are 
presented in this section and analysis of EIAV integration in murine cells is described 
in the next section.  The data are summarized in Table 2-2 and Figures 2-3 and 2-4. 
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Figure 2-2.  Integration site consensus sequence for lentiviral infection of murine 
control and LEDGF/p75-disrupted cells.  A. HIV in +/+ MEFs.  B. HIV integration 
in -/- MEFs.  C. EIAV integration in +/+ MEFs.  D. EIAV integration in -/- MEFs. 
The diagrams were generated using the WebLOGO program (weblogo.berkeley.edu).  
The y-axis indicates bits of information – perfect conservation of a base would score 
as two bits.
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HIV integration in transcription units was decreased in the -/- LEDGF/p75 
gene trap cells compared with wild-type.  In wild-type cells, 54.3% of experimental 
integration sites were in RefSeq genes (see Table 2-2), a significant enrichment over 
the 28% seen in the matched random controls (see Figure 2-3).  In -/- MEFs, 38.7% 
of sites were in RefSeq transcription units, a value that is significantly less than in the 
+/+ MEFs (p<0.0001 by the Fisher’s exact test).  Significant differences were seen 
when the analysis was repeated using other gene catalogs as well (Table 2-2). 
We also analyzed the proximity of HIV integration sites to CpG islands.  In 
wild-type cells integration within 2kb of CpG islands was significantly disfavored 
compared with random, while in knockout cells integration was 10-fold enriched over 
random (P<0.0001 for the comparison between genotypes) 
The frequency of integration within 5kb of RefSeq gene 5’ ends showed a 
similar pattern (Table 2-2).  Integration levels around gene 5’ ends were significantly 
higher than random in the +/+ cells (10.9% of sites), but in the knockout a further 
increase was observed (15.5% of sites within 5kb of gene 5’ end) achieving P=0.014 
for the comparison between cell types (Fisher’s exact test). 
Knockdown of LEDGF/p75 has previously been shown to result in an 
increase in the G/C content of HIV integration site sequences [40].  We therefore 
analyzed the frequency of integration in regions of varying G/C content (Figure 2-3), 
revealing that integration was significantly increased in more G/C rich regions in the -
/- MEFs (P=4e-16).   
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Table 2-2.  Integration frequency in the presence and absence of LEDGF/p75 
near mapped genomic features in the murine genome.  Significant deviation from 
matched random controls according to the Fisher’s exact test is denoted by * 
(***p<0.0001, **p<0.01, *p<0.05). The ‘random control’ set shown is the matched 
random control set for the ‘HIV in +/+ MEF’ integration set (see Materials and 
Methods for generation of matched random controls). 
 
Known RefSeq Ensemble
HIV in -/- 
MEF
42.9*** 38.7*** 46.0*** 6.5*** 15.5***
EIAV in +/+ 
MEF
62.9*** 58.6*** 64.3*** 1.4 5.7
EIAV in -/- 
MEF
41.9 38.4 45.3 12.8*** 25.6***
Random 
Control
29.7 28 32 1.7 6.8
HIV in +/+ 
MEF
Frequency in Genomic Feature (%)
Data Set Transcription Units
<2kb CpG Island <5kb Gene 5' End
10.9***58.6*** 54.3*** 60.7*** 0.7*
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Figure 2-3.  HIV integration distributions in control and LEDGF/p75-disrupted 
cells.  Integration site distributions are shown relative to genomic features. A. 
RefSeq genes. B. CpG islands (plus or minus 1 kb). C.  G/C content.  Integration 
sites from unmodified and knockdown cells were pooled and divided into 10 equal 
bins of increasing GC content, and sites in each cell type plotted for each bin. D. 
Gene density (250kb window). E. Relative gene expression intensity. For each value 
in A-B and D, the measured value for the integration site population was divided by 
that of the matched random control to emphasize the departure of the experimental 
data from random.  P values shown are based on regression analysis (A-C) or Chi 
Square test for trend (D-E).
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A variety of features analyzed did not show significant differences between 
genotypes, including the response to gene density (Figure 2-3D) and the relationship 
between gene activity and integration frequency (Figure 2-3E).  We return to the 
implications of these findings in the Discussion. 
EIAV integration targeting in murine cells disrupted at LEDGF/p75 
Consistent with previous reports [31], EIAV’s integration distribution was 
similar to HIV’s.  Likewise, the effect of LEDGF/p75 was similar.  Integration in 
transcription units was decreased in the -/- LEDGF/p75 gene trap cells compared with 
wild-type, from 58.6% of sites (see Table 2-2 and Figure 2-4) to 38.4% (p=0.016 for 
the comparison between genotypes by the Fisher’s exact test). 
We also analyzed the proximity of EIAV integration sites to CpG islands and 
gene 5’ ends.  In wild-type cells integration within 2kb of CpG islands was not 
significantly different from random, while in knockout cells integration was 13-fold 
enriched over random (P=0.0086; Fisher's exact test).  Similarly, integration levels 
around gene 5’ ends were not significantly different from random in the +/+ cells 
(5.7% of sites), whereas in the knockout a significant enrichment was observed 
(25.6% of sites) achieving P=0.014 for the comparison between cell types (Fisher’s 
exact test). 
We analyzed the correlation between integration frequency and G/C content 
using a 5kb window around the integration site.  A significant difference between 
genotypes was found, with sites from -/- cells being found in more G/C-rich regions 
(P=0.001, using regression analysis, Figure 2-4). 
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Figure 2-4.  EIAV integration distributions in control and LEDGF/p75-
disrupted cells.  Integration frequencies are shown relative to A) RefSeq genes, B) 
CpG islands  (1 kb window; note that there were no control sites within <1kb), C)  
G/C content, D) Gene density (250kb window), E) Gene activity.  Markings as in 
Figure 2-3.
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As seen above for HIV, the frequency of integration near a variety of features 
was not detectably altered.  Figure 2-4D and E show that the relationships between 
integration frequency and gene density and expression were not affected by 
LEDGF/p75 genotype. 
Studies of lentiviral integration in human SupT1 cells with intensified knockdown of 
LEDGF/p75 
 This work was carried out collaboratively with Heather Marshall, also in the 
Bushman lab.  She carried out studies of HIV and EIAV infection and EIAV 
integration site selection in a human model of LEDGF/p75 depletion, intensified 
knockdown SupT1 cells (the TC2 and TL2 cell lines in [37]).  Results from human 
cells were in strong agreement with those from murine cells presented here.  HIV and 
EIAV infection were approximately 10-fold reduced in knockdown cells compared 
with wild-type or scrambled siRNA-expressing cells (data not shown). 
The integration site distribution of EIAV was also altered, and the effects 
were in agreement with those described above for murine cells.  The frequency of 
integration in transcription units in knockdown cells was significantly reduced 
compared with control cells, but the proportion of sites in transcription units in 
knockdown cells remained enriched compared with random (data not shown).  
Integration within 2kb of CpG islands was also enriched in the human cells (data not 
shown).  In agreement with the data described above, integration preference with 
respect to gene density and gene expression was not detectably affected by 
LEDGF/p75 depletion (data not shown). 
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Correlation between LEDGF/p75 expression and the frequency of HIV integration in 
transcription units analyzed over many cell types 
 In addition to studying cells with artificially reduced levels of LEDGF/p75 
expression, we were interested in natural variation in cellular LEDGF/p75 expression 
levels.  Different primary cell types and cell lines show different steady state levels of 
LEDGF/p75 mRNA.  Different cell types also show reproducibly different 
frequencies of HIV integration in transcription units (see [40] for examples).  We thus 
asked whether cell types with higher LEDGF/p75 levels showed higher frequencies 
of HIV integration in transcription units. 
 We analyzed data from 15 HIV integration site data sets for which we also 
had transcriptional profiling data on gene activity for that cell type.  For each 
microarray data set, the expression level of LEDGF/p75-specific probe sets was 
ranked relative to all other probe sets on the array for that cell type, thus yielding a 
value for relative LEDGF/p75 expression.  These values were then plotted against the 
proportion of HIV integration sites in transcription units for that cell type (Figure 2-
5).  This analysis showed that increased relative LEDGF/p75 mRNA abundance 
positively correlated with increased HIV integration frequency in transcription units 
(R2=0.61; P<0.0001).  Figure 2-5 shows data with experimental LEDGF/p75 
knockdowns included (triangles), but the correlation was still significant when the 
experimental knockdowns were excluded (P<0.0001), indicating that natural variation 
in LEDGF/p75 levels was functionally significant.   
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Figure 2-5.  Correlation between LEDGF/p75 expression and the frequency of 
HIV integration in genes.  Data is shown for 15 HIV integration site data sets in 10 
cell types.  The y-axis shows the percentage of integration events within transcrip-
tion units of the "known gene" set of human genes for each integration site data set.  
The x-axis shows relative expression values for LEDGF/p75 derived from Affyme-
trix array data (see methods for details).  The R-squared value for the fit is 0.6148 
(P<0.0001).  The references for the data sets used are as follows:  Macrophage 1 is 
the VSV-G set in [25]; Macrophage 2 is the CCR5 set in [25]; SupT1 [21]; IMR90 1 
is the dividing set in [66]; IMR90 2 is the growth-arrested set in [66]; CD4 T [67]; 
PBMC [22]; Jurkat 1 is the Mse set in [46]; Jurkat 2 is the Avr set in [46]; Jurkat 3 is 
the initially bright set in [5]; Jurkat 4 is the initially dark set in [5]; Jurkat p75 knock-
down [40][46]; 293T [40]; 293T Scram [40]; 293T p75 knockdown [40].
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 Some of the data in Figure 2-5 and in previous studies was generated using 
transformed cell lines, leaving open the question of whether natural variation in 
LEDGF/p75 levels was functionally important in human primary cells.  We repeated 
the analysis in Figure 2-5 using only data from human primary cells where 
LEDGF/p75 levels had not been altered experimentally, and again found a significant 
positive correlation between integration frequency in genes and LEDGF/p75 mRNA 
levels (P=0.044).  These data indicate that natural variation in LEDGF/p75 expression 
levels is a significant determinant of integration frequency in transcription units in 
human primary cells. 
2.5 Discussion 
 Here we report studies of lentiviral integration in murine cells with a 
homozygous gene-trap mutation disrupting the LEDGF/p75 locus [42].  We present 
data from HIV and EIAV, extending the collection of lentiviruses shown functionally 
to be affected by LEDGF/p75.  Infectivity for both HIV and EIAV was reduced 5-50 
fold in LEDGF/p75-depleted cells, in good agreement with data on HIV and FIV 
published previously [37, 41] – taken together, these studies firmly establishing that 
strong LEDGF/p75 knockdowns strongly reduce HIV infectivity.  In data not shown, 
target site selection in human cells closely paralleled the effects in murine cells, and 
also parallel with studies of another murine LEDGF/p75 mutant [37, 41]. 
 Published studies of integration targeting by LEDGF/p75 have relied on 
analysis of cells where the LEDGF/p75 levels were artificially reduced – thus there is 
interest in obtaining data on the effects of LEDGF/p75 in cells naturally expressing 
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different levels of the protein.  We took advantage of the observation that different 
cell types differ reproducibly in their frequency of integration in transcription units 
[40] to investigate this question.  A bioinformatic comparison (Figure 2-5) showed 
that higher levels of LEDGF/p75 expression correlated with higher frequencies of 
integration in transcription units.  The trend achieved significance even when the 
analysis was restricted to human primary cells only.  Thus the study of natural 
variation in LEDGF/p75 expression allowed us to extend the idea that LEDGF/p75 
directs HIV integration to transcription units in human primary cells without 
artificially reduced LEDGF/p75 levels. 
A simple model holds that LEDGF/p75 directs favored integration into 
transcription units by tethering.  According to this model, one domain of LEDGF/p75 
binds to HIV preintegration complexes and the other binds chromatin at active 
transcription units.  Data from artificial tethering studies in vitro with fusions of the 
LEDGF/p75 IBD to a sequence-specific binding domain support this model [56].  
The tethering model predicts that LEDGF/p75 should accumulate on active 
transcription units, but so far this has not been demonstrated experimentally.  
Similarly, it is not known how LEDGF/p75 recognizes active transcription units.  One 
possible model would be that histone post-translational modifications mark active 
transcription units and guide LEDGF/p75 binding.  Potentially consistent with this 
idea is the finding that HIV integration is positively correlated with several types of 
histone post-translational modifications [46]. 
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 Curiously, both this study and Shun et al. [41] showed not only a loss of 
integration targeting in LEDGF/p75-depleted cells, but new favored genomic regions 
as well.  From the previous study alone this might have been an idiosyncrasy, but data 
presented here shows a similar response in a second murine model, and in human 
cells.  In all LEDGF/p75-depleted cell types in both studies, integration became more 
favored near transcription start sites and associated CpG islands.  The basis for this 
trend is unknown.  It may be that preintegration complexes normally associated with 
LEDGF/p75 become free to integrate near these sites once LEDGF/p75 was removed.  
Possibly chromatin at start site regions is particularly accessible and so represents a 
default target.  It is also possible that a more active mechanism is involved.  In 
support of this idea is the finding that MLV integration is strongly favored at start 
sites [28, 57], while several other integrating elements show near random 
distributions [22, 55, 58], suggesting that mechanisms exist to guide preferential 
integration near start sites. 
A variety of genomic features showed positive correlation with lentiviral 
integration in both the depleted cells and controls, indicating that cellular systems in 
addition to LEDGF/p75 also influence integration.  As increasingly deep annotation 
of the human genome accumulates, it may be possible to detect additional 
associations between lentiviral integration and particular bound proteins, potentially 
allowing identification of host cell factors operating in the absence of LEDGF/p75. 
 Finally, data presented here and in [37, 41] emphasizes that LEDGF/p75 is 
important for efficient HIV replication, suggesting that the interaction between IN 
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and LEDGF/p75 may be a tractable target for antiviral therapy.  The structure of a 
complex of the LEDGF/p75 IBD and the IN catalytic domain have been solved by X-
ray crystallography [33], and the interaction surface was found to overlap with the 
binding site seen previously for the integrase inhibitor tetraphenylarsonium [59].  
This supports the idea that small molecule inhibitors, if of high enough affinity, may 
be able to disrupt binding of LEDGF/p75 to integrase and so abrogate HIV 
replication. 
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CHAPTER 3 – LEDGF/P75 HYBRIDS RETARGET LENTIVIRAL 
INTEGRATION INTO HETEROCHROMATIN 
 
The contents of this chapter have been published as part of: 
Gijsbers R, Ronen K, Vets S, Malani N, De Rijck J, McNeely M, Bushman FD 
and Debyser Z. (2010) LEDGF hybrids efficiently retarget lentiviral integration 
into heterochromatin. Mol Ther advance online publication Jan 5, 2010. 
 
3.1 Abstract 
Correction of genetic diseases requires integration of the therapeutic gene 
copy into the genome of patient cells. Retroviruses are commonly used as delivery 
vehicles because of their precise integration mechanism, but their use has led to 
adverse events in which vector integration activated proto-oncogenes and contributed 
to leukemogenesis. Here we show that integration by lentiviral vectors can be 
targeted away from genes using an artificial tethering factor. During normal lentivirus 
infection, the host cell encoded transcriptional co-activator LEDGF/p75 binds 
lentiviral integrase, thereby targeting integration to active transcription units and 
increasing the efficiency of infection. We replaced the LEDGF/p75 chromatin 
interaction binding domain with CBX1. CBX1 binds histone H3 di- or tri-methylated 
on K9, which is associated with pericentric heterochromatin and intergenic regions. 
The chimeric protein supported efficient transduction of lentiviral vectors and 
directed integration outside of genes, near bound CBX1. Despite integration in 
regions rich in epigenetic marks associated with gene silencing, lentiviral vector 
expression remained efficient. Thus engineered LEDGF/p75 chimeras provide 
technology for controlling integration site selection by lentiviral vectors.  
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3.2 Introduction 
Lens epithelium-derived growth factor/p75 (LEDGF/p75) is a transcriptional 
co-activator [1, 2] that colocalizes with chromatin [3] and interacts with the integrase 
(IN) of the human immunodeficiency virus type 1 (HIV-1) and other lentivirinae [4-
7]. RNAi-mediated depletion of LEDGF/p75 results in the relocalization of IN to the 
cytoplasm and blocks HIV replication at the integration step of the viral lifecycle [8-
11]. In addition, LEDGF/p75 depletion alters the genomic distribution of lentiviral 
integration sites [12-14]. Lentiviruses preferentially integrate in active transcription 
units and disfavor promoter regions and locations within 1kb of CpG islands [13-17]. 
For both HIV and EIAV (Equine Infectious Anemia Virus), integration in 
LEDGF/p75-depleted cells is reduced in transcription units, but increased in regions 
of relatively high GC content and gene 5’ ends. A model has therefore been proposed 
in which LEDGF/p75 functions as a molecular tether, bridging between IN and host 
chromatin [11-18]. 
The integrase binding domain (IBD) alone does not mediate chromatin 
binding, but overexpression relocates HIV IN to the cytoplasm and blocks HIV 
replication [18,19], likely by blocking function of full length LEDGF/p75. The 
mechanism of chromatin association by LEDGF/p75 is poorly understood, but an N-
terminal PWWP domain [20], a nuclear localization signal, and two AT hooks are 
implicated as important from functional studies [11, 21-23] (Figure 3-1).  
Meehan and colleagues recently showed that LEDGF proteins bearing H1.1, 
H1.5 and LANA in place of LEDGF’s first 199 amino acids are functional HIV-1 
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Figure 3-1. Domain structure of LEDGF/p75 and schematic representation 
of LEDGF325-530 fusions. LEDGF/p75 contains an integrase-binding domain 
(IBD) in the C-terminus and a combination of chromatin interacting modules 
located in the N-terminal end, most notably the PWWP-domain, the AT-hook 
domain, and three relatively charged regions (CR1-CR3) influence chromatin 
binding. In the lower panel the DNA-binding domain fusions with LEDGF325-530 
are depicted, H1-LEDGF325-530 and CBX1-LEDGF325-530, respectively. Protein 
elements are drawn to scale. Numbers indicate amino acids of each domain. NLS, 
nuclear localization signal; H1, histone H1; CBX1, heterochromatin protein 1β 
(formerly HP1β).
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cofactors [24]. Here we used the LEDGF-IN interaction to retarget lentiviral 
integration to alternative regions of the genome. We engineered artificial chromatin 
tethers by fusing the C-terminal IN binding fragment of LEDGF/p75 to alternative 
chromatin binding proteins, expressed these in LEDGF/p75-depleted cells, and asked 
whether 1) infection was rescued and 2) integration was retargeted to the regions 
bound by the chimeric protein. In a previous study, Ciuffi et al. created fusions of 
LEDGF/p75 IBD and the λ repressor DNA binding domain and found increased in 
vitro strand transfer activity near λ repressor binding sites [25]. However, this 
approach has not yet been used to redirect viral integration in cells.  
We compared integration targeting for many hybrids between chromatin 
binding proteins and LEDGF/p75, with particular focus on domains with binding 
specificities that might be useful during human gene therapy. The heterochromatin 
protein 1β (CBX1, formerly HP1β) binds to sites enriched in histone H3K9 di- and 
tri-methylation at centromeric heterochromatin and transcriptionally silent regions 
[29, 38, 39].  This provides a chromosomal target present at high copy number in 
gene sparse regions. We found that a fusion in which CBX1 replaced the chromatin-
interaction domain of LEDGF/p75 rescued the infection block in LEDGF/p75-
depleted cells. We characterized proviral integration sites using 454 pyrosequencing 
and found integration to be retargeted in the presence of the fusion to genomic sites 
bound by CBX1. These regions are preferentially outside transcription units and 
normally disfavored for lentiviral integration, but transgene expression from the 
vector was nevertheless efficient. These findings open possibilities for targeting of 
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gene therapy vectors by using the LEDGF/p75-IN interaction, potentially to gene-
poor regions where their genotoxic potential may be reduced.  
3.3 Materials and methods 
Retroviral vector production and transduction 
Lentiviral vector production was performed as described [34, 50]. Briefly, 
vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped HIV-based particles 
were produced by PEI transfection using pCHMWS_eGFP-T2A-fLuc as a transfer 
plasmid [34]. EIAV-vector particles were produced likewise using p6.1G3CeGFPw 
(M. Patel & J. Olsen, University of North Carolina, Chapel Hill, unpublished) and 
pEV53B and VSV-G encoding pMD.G.  
For lentiviral transduction experiments, cells were typically plated at 
20,000 cells/well in a 96-well plate and transduced overnight. 72 hours later, 90% of 
cells were reseeded into two plates (FACS analysis and Luc-assay). The remainder 
was cultured for Q-PCR or integration site analysis for at least 20 days to eliminate 
non-integrated DNA. Stable cell lines were generated by transduction of the 
monoclonal LEDGF/p75 KD cells with retroviral vectors and subsequent selection 
with blasticidin (3 µg/ml; Invitrogen, Merelbeke, Belgium).  
Q-PCR 
 Integrated proviral copies were quantified by real-time Q-PCR on gDNA as 
reported earlier [13]. 
Integration site amplification 
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Integration sites were amplified by linker-mediated PCR as described 
previously [13]. gDNA was digested using MseI and linkers were ligated. Proviral-
host junctions were amplified by nested PCR using barcoded primers. This enabled 
pooling of PCR products into one sequencing reaction. Products were gel-purified 
and sequenced on the 454 GS-FLX instrument at the University of Pennsylvania. 
Oligos used are listed below: 
 
Bioinformatic analysis 
For integration sites to be called as authentic, sequences needed a best unique 
hit when aligned to the human genome (hg18 draft) using BLAT, the alignment 
needed to begin within 3bp of the viral LTR end, and the sequence needed to show a 
>98% match to the human genome. Statistical methods are detailed in Berry et al 
[37]. Integration site counts were compared with matched random controls (MRCs) 
by a Fisher’s exact test (where stated), or by multiple regression models for 
integration intensity and a c-logit test for significance [37]. Analysis was carried out 
using R (http://www.r-project.org). Histone modification data from Barski et al. [40] 
and Wang et al. [41] were used. The number of sequence tags from the ChIP-Solexa 
data sets in a defined window around each EIAV integration site or MRC, was 
calculated. CBX1 binding sites were analyzed using data from Vogel et al. [44]. For 
each DamID probe set available, probes were aligned onto the hg18 draft using 
Primer Sequence
EIAV PCR1 CCTGTCTCTAGTTTGTCTGTTCG 
EIAV nested PCR2 (454 primer B-barcode-EIAV) gccttgccagcccgctcagxxxxxxxxAGTTTGTCTGTTCGAGATCCTAC
Linker PCR1 GTAATACGACTCACTATAGGGC
Linker PCR2 (454 primer A-linker) gcctccctcgcgccatcagAGGGCTCCGCTTAAGGGAC 
Mse linker+ GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC
Mse linker- [Phosp]TAGTCCCTTAAGCGGAG-[AmC7-Q]
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BLAT, and their associated log2 binding ratios used to select the top 5% of sites. For 
each integration site or MRC the average number of high-affinity probes within a 
defined window around the site was calculated.  Pericentric regions were defined as 
1Mb upstream or downstream of the unsequenced gap on each chromosome. 
3.4 Results 
Generation of cell lines and LEDGF/p75 fusions 
This study was conducted in collaboration with Rik Gijsbers from the Debyser 
lab.  Rik transduced HeLaP4-CCR5 cells with an MLV-based expression vector 
encoding  two miRNA-based shRNAs [26] and a zeocin resistance cassette to 
generate a monoclonal cell line expressing 4% of parental LEDGF/p75 mRNA. 
Rik also generated constructs where LEDGF/p75’s chromatin binding region 
(aa 1-324, Figure 3-1) was replaced by alternative DNA-binding proteins. LEDGF325-
530 was fused to linker histone 1 (H1; histone 1, H1F0) and heterochromatin protein 
1β (CBX1, formerly HP1β). H1F0 binds to nucleosomes without apparent preference 
for the underlying DNA sequence [27], continuously shuttling among chromatin 
binding sites [27]. CBX1 is associated with pericentric heterochromatin. CBX1 has a 
single N-terminal chromodomain which recognizes histone tails via methylated lysine 
residues, for example tri-methylated histone H3 at lysine 9 (H3K9me3) [29, 38, 39]. 
Both constructs, referred to as H1-LEDGF325-530 and CBX1-LEDGF325-530, were 
introduced in LEDGF/p75 depleted cell lines using MLV-based viral vectors and 
selected with blasticidin. In parallel, control cell lines complemented with MLV-
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based vectors encoding RNAi-resistant LEDGF/p75 (LEDGF BC) or eGFP-
LEDGF325-530 were generated. 
Viability of the selected cell lines was similar to the parental HeLaP4-CCR5 
cell line (data not shown). Expression of the fusion proteins in the knockdown cell 
line (referred to as KD) was verified by Western blot and immunocytochemistry with 
an antibody against the C-terminal portion of LEDGF/p75 (data not shown).  No 
LEDGF/p75 expression could be detected in KD cells.  Back-complementation of KD 
cells with full-length siRNA-resistant LEDGF/p75 resulted in the expression pattern 
characterstic of LEDGF/p75, which is dense fine nuclear speckling.  
Complementation of KD cells with the H1-LEDGF325-530 fusion resulted in a nuclear 
distribution and CBX1-LEDGF325-530 which was distributed in multiple irregularly 
shaped foci over the nuclear area during interphase, a pattern paralleling that of wild-
type CBX1 [32,33].  In addition to nuclear localization, LEDGF/p75 fusion proteins 
were found to mediate chromatin tethering of HIV IN. In accordance with previous 
data [3,4], transient expression of IN fused to the monomeric red fluorescent protein 
(mRFP-INs) in KD cells resulted in a diffuse fluorescent signal throughout the 
cytoplasm and complementation with LEDGF/p75 relocated mRFP-INs to the nucleus 
and condensed chromatin. Expression of H1-LEDGF325-530 and CBX1-LEDGF325-530 
rescued the nuclear localization of mRFP-INs and the binding to condensed chromatin 
(data not shown). 
LEDGF hybrids rescue lentiviral transduction 
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After demonstrating that the fusions were capable of interacting with HIV-1 
IN and tethering IN to chromatin, Rik Gijsbers also assayed the efficiency of 
integration by lentiviral vectors.  In addition to interacting with HIV IN, LEDGF/p75 
is known to interact with other lentiviral integrases [4-5].  Integrated HIV- and EIAV-
based vector proviral copies were quantified in the different cell lines. For HIV, KD 
cells showed a 5.8-fold decrease in integrated copies compared with wild-type cells, 
which was rescued completely upon back-complementation with full-length RNAi-
resistant LEDGF/p75. Expression of fusion proteins partially rescued integration 
(60% and 41% of LEDGF BC integration for H1- and CBX1-LEDGF325-530, 
respectively).   Similarly, for EIAV, the number of integrated copies in KD cells was 
decreased 8.8-fold compared to wild-type cells. Complementing the KD cells with 
H1-LEDGF325-530 and CBX1-LEDGF325-530 resulted in a partial rescue of vector 
integration (3.3-fold and 6.9-fold increase over KD respectively). Thus expression of 
the chimeric proteins partially rescued EIAV and HIV integration. 
Sequencing of proviral integration sites 
We next asked whether the LEDGF325-530 fusions retargeted integration to 
genomic sites bound by the fusion partner. Since HeLaP4 cells contain integrated 
HIV LTRs that would interfere with the isolation of HIV provirus, we used the EIAV 
vector for distribution analysis. EIAV and HIV integrase both interact with the 
LEDGF/p75 IBD [6] and show the same integration site preferences in wild-type [35] 
or LEDGF/p75-depleted [13] cells. Integration sites were analyzed as described 
previously [13], yielding a total of 2769 integration sites (Table 3-1). Random control 
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Table 3-1. Integration sets generated in this study and their genomic 
distributions.  Significant deviation from matched random controls (MRC) according 
to the Fisher’s exact test is denoted (*** p<0.0001, ** p<0.01, * p<0.05). 
 
Cell line
Number of 
sites
% in RefSeq 
genes
% <2kb CpG 
Island
Wild-type 717 67.2*** 1.3
Back-complemented 862 70.2*** 1.9
Knockdown 213 51.2*** 5.6**
H1-LEDGF325-530 449 46.1** 3.3
CBX1-LEDGF325-530 528 32.6* 1.1
MRC WT 2151 37.3 2.8
MRC BC 2586 36.9 2.1
MRC KD 639 36.5 1.9
MRC H1 1347 36.8 2.2
MRC CBX1 1584 37.8 2.1
EIAV sites
MRC sites
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sites were generated computationally, and matched to experimental sites with respect 
to the distance to the nearest MseI cleavage site (matched random control, MRC). In 
the analyses that follow, the distribution of experimental EIAV sites is normalized to 
that of the MRC sites, as a control for recovery bias due to cleavage by restriction 
enzymes [36, 37]. 
Retroviral integrases show weak but detectable target sequence specificity at 
the local site of integration. In line with previous reports [13,14], LEDGF/p75 
depletion did not affect the consensus sequence flanking the integration site (Figure 
3-2). Likewise, expression of LEDGF325-530 fusions did not alter the consensus 
sequence, consistent with the idea that IN binding to local target DNA determines the 
sequence preference, independently of the tethering mechanism. 
CBX1-fusion directs integration to intergenic regions 
Lentiviruses favor integration in transcription units and gene-dense regions 
[15, 35]. In the absence of LEDGF/p75 this preference is reduced, and a preference 
for CpG islands and gene 5’ ends emerges [12-14]. As an initial survey of the proviral 
integration site distribution, we examined the frequency of integration in these 
features. In KD cells a reduction in the integration frequency in RefSeq transcription 
units from 67.2% to 51.2% was observed (Table 3-1 and Figure 3-3A), as previously 
reported for LEDGF/p75-depleted cells [13]. While this reduction was statistically 
significant (p<0.0001, Fisher’s exact test), integration events in the KD cells were 
still significantly favored in transcription units over random (p=4.8 e-6). In 
accordance with previous reports, we found that integration sites in the KD cells were 
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Figure 3-2. EIAV integration site consensus is not affected by LEDGF/p75 
fusions.  Following alignment of 20 bp surrounding EIAV integration sites from 
each cell type, a consensus sequence was generated using the WebLogo program 
(weblogo.berkeley.edu/logo/cgi). Consensus sequence for integration sites from 
A. WT cells B. KD cells C. cells complemented with full-length LEDGF/p75 D. 
cells stably expressing H1-LEDGF325-530 E. cells stably expressing CBX1-
LEDGF325-530. The x-axis shows the position relative to the integration site 
(between position -1 and 0). The y-axis shows bits of information at each posi-
tion (perfect conservation at a position would score 2 bits).
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Figure 3-3. Expression of the CBX1 fusion retargets EIAV integration away from 
expressed genes.  A. Frequency of integration within transcription units, as defined by 
the RefSeq gene call.  Values are normalized to matched random controls.  Asterisks 
signify significant deviation from matched random controls, determined by the 
Fisher’s exact test. *p<0.05, **p<0.01, ***p<0.0001   B. Distribution of integration 
sites with respect to gene expression.  Transcriptional profiling data from wild-type 
HeLa cells analyzed on the HU133 Affymetrix microarray were used to classify the 
expression of genes harboring EIAV integration sites. Genes represented on the 
microarray were ranked by expression level and divided into 4 bins. For each cell line, 
integration sites found within genes were sorted into the 4 bins. The percentages 
shown are the proprtions of sites in each bin out of sites falling in all expression bins.
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favored near CpG islands. Both trends were reversed by LEDGF/p75 back-
complementation. In contrast, expression of H1-LEDGF325-530 did not rescue 
integration in transcription units. However, upon expression of CBX1-LEDGF325-530, 
integration was significantly disfavored in transcription units compared with random 
(p=0.026, Fisher’s exact test), consistent with the distribution pattern of CBX1 in 
heterochromatic regions, which are generally gene-poor.  Analysis of the distribution 
of integration sites with respect to gene expression level of the targeted genes also 
provided evidence of retargeting due to expression of the CBX1-LEDGF fusion.  
Figure 3-3B shows that EIAV integration sites falling in transcription units showed a 
slight shift towards genes with lower expression level according to microarray 
analysis of HeLa cells (p<0.0001, comparing CBX1-LEDGF325-530 and WT cells by 
the Chi Square test for trend). 
CBX1-fusion directs integration to heterochromatic regions 
CBX1 is known to bind H3 di- or tri-methylated at K9 (H3K9me2 and 
H3K9me3, respectively) via its chromodomain [29, 38, 39], so we investigated 
integration near sites of these histone modifications [40, 41]. The H3K9me3 density 
near sites of EIAV integration is summarized in Figure 3-4A. In WT cells, integration 
was disfavored in areas high in H3K9me3 (p=2.9 e-29), consistent with the role of 
H3K9me3 in transcriptional repression and establishment of silent heterochromatin, 
features generally disfavored by lentiviral integration. In the KD cells the same 
negative correlation remained, though its magnitude was reduced (p=0.0012). 
Complementation with LEDGF/p75 restored the negative effect of H3K9me3 to wild-
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Figure 3-4. Expression of the CBX1 fusion retargets EIAV integration into 
CBX1-rich heterochromatin regions.  A. Relationship of integration frequency to 
sites of H3K9me3 (10kb window around each site). B. Integration frequency relative 
to density of histone methylation and acetylation density (10kb window around sites). 
C. Integration frequency in pericentromeric regions (defined as 1 Mb at the edge of 
unsequenced centromeric regions). D. Integration frequency in human chromosome 
19 near CBX1 binding sites.  See Materials and Methods for detailed explanation of 
anaylsis.
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type levels. Integration site distribution in H1-LEDGF325-530 cells paralleled that seen 
in KD cells. In cells expressing CBX1-LEDGF325-530, however, the correlation was 
reversed, with integration sites showing a clear preference for regions denser in 
H3K9me3 (p=1.3 e-13).  
We carried out the same analysis using genome-wide ChIP-seq data for a 
panel of 39 histone modifications [41].  Figure 3-4B shows correlations between 
integration sites and the density of these modifications. Each correlation is 
represented as a tile on the heat map, with the color denoting the strength and 
direction of the correlation. Histone modifications are grouped into clusters, reported 
to colocalize and associate with classes of functional genomic elements [41]. In wild-
type cells, EIAV sites positively correlated with histone modifications generally 
associated with active transcription, such as all acetylations, and some histone 
methylations (shown in blue). Integration sites in wild-type cells negatively correlated 
(shown in yellow) with H3K9me3 and other markers reported to be associated with 
transcriptionally silent regions (e.g. H3K27me3) and heterochromatin (e.g. 
H4K20me3 and H3K79me3) [40, 42, 43]. In KD cells, most of the correlations 
persisted, though they were less pronounced. Complementation with LEDGF restored 
correlations to wild-type levels. In cells expressing CBX1-LEDGF325-530, however, 
most of the correlations were reversed, suggesting a dramatic redistribution of 
integration sites. In addition to H3K9me3, the modification bound by CBX1, regions 
high in H4K20me3 and H3K79me3 became favored for EIAV integration. The latter 
two modifications have also been associated with pericentric heterochromatin.  
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Since CBX1 is enriched around centromeres, we compared the frequency of 
integration sites in pericentric regions. Integration sites in WT, KD or LEDGF BC 
cells did not differ from random (Figure 3-4C). In contrast, in cells expressing CBX1-
LEDGF325-530, these regions contained 2.7-fold as many integration sites as MRC 
sites (p=0.0052, Fisher’s exact test), significantly higher than KD cells (p=0.0236, 
Fisher’s exact test). Sites from H1-LEDGF325-530 cells also showed a preference for 
these regions, but this was not significantly higher than KD cells (p=0.0851, Fisher’s 
exact test). 
Finally, we used CBX1 binding sites mapped by DamID [44] to calculate the 
average number of CBX1 binding sites around integration sites. Figure 3-4D shows 
CBX1 occupancy around EIAV integration sites on chromosome 19 did not differ 
from random in wild-type cells and KD cells, and was not altered in H1-LEDGF325-530 
expressing cells. However, in cells complemented with the CBX1 fusion, 10kb 
windows around integration sites contain 7 times as many CBX1 binding sites as 
random (p=2.5 e-4). The same pattern held when integration sites across the genome 
were compared to CBX1 binding sites mapped genome-wide (p=0.015, not shown). 
Thus the CBX1-LEDGF/p75 fusion redirected integration to sites known to bind 
CBX1 and a collection of associated features. 
Reporter gene expression remains efficient over time 
Having shown that the CBX1-LEDGF325-530 fusion retargets lentiviral 
integration to sites bound by CBX1, we wondered whether gene expression from the 
vector remains efficient, despite integration in regions rich in epigenetic marks 
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associated with gene silencing.  Heterochromatin is known to spread to surrounding 
chromatin – indeed CBX1 and the other HP1 isoforms are thought to enable this 
propagation, by binding trimethylated H3K9 and recruiting the methyltransferase 
responsible for depositing the modification, Suv39 [29].  This is thought to account 
for the phenomenon of position-effect variegation, an effect first described in 
Drosophila, where chromosome rearrangements resulting in the positioning of a gene 
adjacent to centromeric heterochromatin resulted in its silencing (reviewed in [51]).  
We therefore wondered whether targeting lentiviral integrants to regions bound by the 
heterochromatin-associated protein CBX1 would have a similar silencing effect. 
Cells lines were infected with an HIV vector expressing luciferase and 
luciferase activity measured by Rik Gijsbers 48h post-infection. Luciferase activity 
was 7-fold lower in KD cells than WT (data not shown) and was rescued by back-
complementation with RNAi-resistant LEDGF.  Fusion of LEDGF325-530 to either the 
linker histone H1 or CBX1 partially rescued viral vector transduction (36.3% and 
47.5%, respectively, data not shown).  Similarly for EIAV, back-complementation of 
KD cells rescued vector transgene expression to wild-type levels and fusion of 
LEDGF325-530 to linker histone H1 or CBX1 partially rescued viral expression (53% 
and 45.1%, respectively, data not shown).  Thus, partial reporter gene expression was 
observed, mirroring the partial integration rescue observed by provirus QPCR. 
We wondered whether the integrants in cells expressing CBX1-LEDGF325-530 
might be silenced over time due to the spread of inhibitory chromatin.  Reporter 
activity was therefore measured over time for the CBX1-LEDGF325-530 cells and 
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compared to WT cells, KD cells or KD cells complemented with full-length 
LEDGF/p75. Engineered cell lines were infected with an HIV-based vector 
expressing eGFP and fLuc [34], and reporter expression was measured in cells over 
two weeks. Mean fluorescence intensity (MFI) gradually decreased in all cell lines 
over time (Figure 3-5). The relative difference in overall MFI (fold difference to the 
first measurement at 72 hrs) reached 4-fold in WT cells or LEDGF BC cells, and 
about 2.5-fold in the KD cells. Surprisingly, eGFP reporter activity only decreased 
1.5-fold in the CBX1-LEDGF325-530 cells, demonstrating that despite retargeting to 
CBX1 binding regions transgene expression remained efficient.  Thus, there was no 
evidence for the idea that integration in more heterochromatic regions directed by the 
CBX1 domain obstructed gene expression from these HIV-based vectors. 
In these studies of lentiviral vectors, reporter gene expression is driven by the 
CMV immediate early promoter.  We wondered if a similar effect would be observed 
with LTR promoter elements.   Cells were therefore infected with replication-
competent HIV (NL4.3 strain) and p24 production quantified over time by ELISA 
(Figure 3-6).  Again, CBX1-LEDGF325-530-expressing cells mediated a partial rescue 
of Gag gene expression, to 26.2% of that in WT cells.  However, in QPCR-based 
assays CBX1-LEDGF325-530 expression mediated 60% rescue of integration, 
suggesting that in this case vector expression efficiency may be reduced.  It therefore 
remains possible that retargeting lentiviral integration to heterochromatic regions 
does influence vector expression, though the effects appear to be modest and 
promoter-specific.  
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Figure 3-5. Effect of retargeting by CBX1-LEDGF325-530 on transgene expression 
over time. WT, KD and LEDGF BC cells were used as controls.  GFP expression 
was assayed at the indicated time point following HIV-based vector (LV CMV 
eGFP-T2A-fLuc) infection (dpi, days post infection). Overall eGFP fluorescence over 
time is calculated as MFI multiplied by % gated cells and displayed as mean ± stdev 
(n=6). Experiment conducted by Rik Gijsbers.
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Figure 3-6. Effect of integration retargeting on HIV (NL4.3) gene expression.  
A. Gag p24 expression, quantified by ELISA at intervals post-infection.  B. Proviral 
copies in cells expressing the different constructs, normalized to the level in back-
complemented cells. Experiments conducted by Rik Gijsbers.
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3.5 Discussion 
In this study, we present evidence that LEDGF/p75 can be engineered to 
target lentiviral integration to new positions in the genome. Alternative chromatin 
binding domains (linker histone H1 or the heterochromatin protein 1β, CBX1, were 
fused to the C-terminal portion of LEDGF/p75 (aa 325-530, LEDGF325-530). CBX1 
was selected to target sites of H3K9 di- and tri-methylation, which are mapped in the 
genome and usually disfavored for lentiviral integration, so retargeting would be 
readily identifiable. H1 was used as a control, since it has no known preference for 
the underlying DNA sequence. Fusing a new chromatin-binding module to 
LEDGF325-530 changed the behavior of this protein from an integration-inhibitor into 
an efficient cofactor. Upon challenge by lentiviral vectors, LEDGF325-530-fusions 
supported efficient lentiviral transduction and integration compared to KD cells. 
Similar data were recently reported by Meehan and co-workers [24], albeit using 
LEDGF-hybrids that only lack the PWWP- and AT-hook domain (aa 1-199). 
In addition, we characterised proviral integration sites using 454 
pyrosequencing. Analysis of the EIAV integration distribution demonstrated that the 
CBX1 fusion retargeted lentiviral integration away from RefSeq genes (Table 3-1), to 
regions high in H3K9me3 (Figure 3-4A) and CBX1 binding (Figure 3-4D). The 
observation that integration can be retargeted away from genes and into 
heterochromatin using LEDGF hybrids raises hope for the development of safer 
lentiviral vectors for gene therapy. Prior to this study, attempts to retarget HIV 
integration employed fusions of IN with DNA-binding proteins [45-48]. Some of 
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these showed retargeting as purified enzymes, but until now this approach had limited 
effect on the distribution of integration sites in cells. 
The CBX1 hybrid provides the first example of global redistribution of 
lentiviral integration sites in the cellular genome, and the first instance of 
manipulation of a host tethering factor to do so. The success of the CBX1 fusion may 
be due to the abundance in the genome of its target ligand compared with site-specific 
DNA binding domains previously employed, or perhaps its level of occupancy. 
Even though integration was targeted towards regions in the genome that are 
generally associated with gene silencing, transgene expression remained efficient 
over time (Figure 3-5).  Similarly, when the effect of retargeting on a replication-
competent HIV strain, NL4.3, was tested (where gene expression is driven by LTR 
promoter elements) Gag-p24 gene expression and infection spread still occurred, 
though there was some evidence that its efficiency might be reduced.  This suggests 
retargeting integration to heterochromatin may have promoter-specific effects.  Based 
on the paradigm of position effect variegation, one might have expected an effect on 
reporter gene expression [51].  The idea that the genomic location of an integrated 
HIV provirus affects its expression would also be consistent with previous studies and 
proposed models of HIV latency [52].  These results therefore warrant further 
investigation.  It may be that expression of the CBX1-LEDGF/p75 fusion protein 
interferes with the spread of heterochromatin mediated by endogenous CBX1. 
Whether new classes of genes are activated as a result is unknown.  Alternatively it 
may be that lentiviral LTRs contain unidentified insulator elements.  To determine the 
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chromatin structure of integrated proviruses, chromatin immunoprecipitation of 
regions of the provirus could be performed.  Another way to determine if proviral 
expression is reduced by retargeting would be to employ the approach of Lewinski et 
al. [52], who looked at genomic features correlating with inducible (instead of 
constitutive) provirus expression.  Cells were infected with GFP Tat-dependent virus, 
selected for stably bright cells and dim but inducible cells and integration site 
distributions were compared.  This could be used to ask if proviruses that express 
poorly are also viruses that show more extreme retargeting. 
Our findings open possibilities to engineer viral vectors that incorporate 
LEDGF/p75 hybrids to target integration into safe landing sites, thereby reducing the 
risk of insertional mutagenesis. Hare and colleagues have recently reported [49] a set 
of amino-acid substitutions in HIV IN that abolish LEDGF/p75 binding, together with 
mutations in the LEDGF/p75 protein that restore binding. Gene delivery vectors 
could thus use an altered IN/LEDGF pair to direct integration, even in the presence of 
wild-type LEDGF/p75. To date the altered IN does not show wild-type integration 
activity, but this may be improved with further engineering. 
Our data also address issues in HIV biology. Our findings strengthen the idea 
that LEDGF/p75 is the dominant tether for lentiviral integration. The fact that 
integration can be retargeted to genomic regions usually disfavored for integration 
indicates that integration in these areas in wild-type cells is disfavored due to the lack 
of a tether, rather than to an inherent integration barrier such as steric hindrance 
resulting from the condensed chromatin structure.  Moreover, we show that 
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chromatin-binding proteins with multiple specificities can successfully replace the 
LEDGF/p75 DNA-binding elements and rescue HIV infection in a LEDGF/p75 
knockdown model. Still, the hybrids did not mediate rescue to wild-type levels, which 
leaves open the question of whether some portions of the N-terminus of LEDGF/p75 
absent from our fusions stimulate integrase activity or reporter gene expression.  
Indeed, a recent study suggested that serine residues 271, 273 and 275 may be 
important in LEDGF/p75 cofactor function without affecting DNA or integrase 
binding [53]. 
In conclusion, these results establish that LEDGF/p75 is the dominant 
targeting factor for lentiviral integration and that its interaction with lentiviral 
integrases can be exploited to develop safe and target-specific lentiviral vectors for 
gene therapy.  
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CHAPTER 4 – INTEGRATION SITE DISTRIBUTION IN MICE 
FOLLOWING THERAPEUTIC GENE TRANSFER TO TREAT β-
THALASSEMIA 
 
The contents of this chapter are being prepared for submission: 
Ronen K, Negre O, Malani N, Denaro M, Gillet-Legrand B, Leboulch P, Down 
JD, Bushman FD. Integration site distribution in mice following therapeutic gene 
transfer to treat beta-thalassemia. 
 
4.1 Abstract 
Treatment of genetic diseases such as β-thalassemia (β-Thal) requires 
covalent integration of therapeutic genes into a patient's chromosome to allow stable 
inheritance.  The Lentiglobin™ lentiviral vector has been applied to gene therapy for 
β-Thal with success in one human patient, but a semi-dominant clonal expansion after 
integration in the HMGA2 locus in this patient raised the question of whether 
lentiviral integration could alter activity of nearby genes and promote abnormal 
cellular growth.  Here we have used a mouse model for therapeutic gene transfer and 
bone marrow transplantation, using the same vector used to treat β-thal patients, and 
investigated the integration site distributions present after 9 months of hematopoietic 
reconstitution in five busulfan pre-treated β-Thal mice.  The recipient mice 
demonstrated correction of the disease and were healthy at time of sacrifice.  The pre-
transplantation integration site distribution was typical of lentiviral vectors, showing 
favored integration in genes and gene-rich regions.  After hematopoeitic cell 
repopulation in mice, integration sites located near genes involved in growth control 
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were not enriched.  No integration sites in or near HMGA2 were detected.  Cells 
containing integration sites in genes became less common after growth in mice than 
before transplantation, and this was accentuated after subsequent culture of explanted 
cells in methylcellulose.  This is consistent with selective loss of cells containing 
integration sites in genes, possibly due to changes in dosage.  Similar results have 
been seen in some but not all previous studies.  Most importantly, these data in mice 
indicate that gene correction can be achieved without any indication of vector-
enhanced cell proliferation. 
4.2 Introduction 
Retroviral vectors have been successfully used in human trials of gene transfer 
to treat a number of genetic diseases, including X-linked severe combined 
immunodeficiency disorder (X-SCID) [1], adenosine deaminase deficiency (ADA-
SCID) [2], chronic granulomatous disease (CGD) [3] and X-linked 
adrenoleukodystrophy (ALD) [4].  However, several adverse events have occurred in 
which integration of the therapeutic vector resulted in insertional activation of proto-
oncogenes, contributing to the development of leukemia [5-9].  Thus there has been 
intense interest in characterizing the integration profile of gene therapy vectors and 
improving their safety. 
While the majority of completed trials of retroviral gene transfer have used 
gammaretroviral vectors, lentiviral vectors are increasingly used.  Their appeal stems 
from several observations.  Lentiviral vectors, unlike gammaretroviral vectors, infect 
non-dividing cells [10].  Additionally, no convincing examples of insertional 
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activation of oncogenes and consequent transformation have been reported associated 
with HIV infection, though HIV proviruses can affect the activity of nearby genes 
[11, 12].  Moreover, studies in tumor-prone mouse models have reported less 
genotoxicity resulting from lentiviral than gammaretroviral transduction [13, 14].  
One possible explanation for the difference in oncogenic potential between lentiviral 
and gammaretroviral vectors may be related to differences in their preferred sites of 
integration in the genome.  Insertional activation in animal models and human 
patients is caused by integrated vector promoter or enhancer elements upregulating 
downstream cellular genes [5, 6, 8, 15-19].  Gammaretroviral vectors show a strong 
propensity to integrate at promoters and gene 5’ ends [20], and clustering near genes 
controlling cell growth and proliferation has been reported [21].  Lentiviruses, on the 
other hand, favor integration in the bodies of transcription units, avoiding regulatory 
5’ regions [22-24], with no bias for growth-associated genes.  The lentiviral 
integration pattern may thus be less likely to result to insertional activation, though 
other variables such as cell type specificity may also play a role [25].  In the context 
of vectors, the engineered transcriptional control elements may also explain the 
observed differences between gammaretroviral and lentviral vectors [13, 14]. 
Three clinical trials have been conducted using lentiviral vectors in humans, 
and in each the genomic distribution of integration sites was monitored.  The first 
tested an anti-HIV therapy by delivering an antisense HIV-env gene to mature T-cells 
[26]. Integration events in these patients showed no evidence of enrichment of sites in 
proto-oncogenes following transduction [27].  The second trial treated two patients 
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with ALD by transduction of hematopoietic stem cells [4].  Integration sites in these 
two patients also showed sustained polyclonality up to 24 months after 
transplantation.  Thirdly, one patient was treated for β-thalassemia by hematopoietic 
stem cell transduction with a lentiviral vector encoding β-globin with clinical success 
(Cavazzana-Calvo et al., submitted).  In the β-Thal trial, the integration site 
distribution determined at 19 months post-transplantation showed that ~50% of 
integration sites were within the proto-oncogene HMGA2.  The integration event was 
associated with increased transcription of HMGA2 and expression of a transcript 
whose 3’ UTR was replaced by vector sequences. This 3’-subsituted transcript lacked 
the target of the repressive miRNA, let-7, contributing to elevated HMGA2 
expression along with an increase in the rate of transcriptional initiation.  HMGA2 
has been implicated as important in persistence of stem cells [28] and is disregulated 
in some cancers, including by disruption of the normal gene 3' end [29-32].  While 
the treated patient remains healthy, this finding has raised questions about the 
possibility of lentiviral integration in or near growth-control genes imparting a 
selective advantage and leading to preferential outgrowth of the gene-modified cell. 
The same SIN lentiviral vector as was used in the β-Thal clinical trial has 
been tested in a preclinical mouse model of β-thalassemia, using a closely related 
transduction protocol (Negre et al., submitted).  This allows further study of the 
vector’s possible genotoxicity, and a comparison of the distribution of integration 
sites in the mouse and human studies.  Nine months post-transplantation the mice 
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showed no apparent pathological abnormalities while demonstrating long-term 
resolution of the hematological abnormalities associated with β-thalassemia. 
Here we present a study of the vector integration sites recovered from bone 
marrow transduction and transplantation of five mice.  We observed oligoclonality of 
integration sites in all animals.  Functional classes of genes close to integration events 
showed no significant enrichment in genes encoding growth-related functions.  
Integration events with the potential to disrupt onocogene regulation by disruption of 
miRNA regulation through the mRNA 3' end were not detectably enriched.   We also 
observed that integration sites from cells following growth either in mice or in 
subsequent cell culture showed a reduced frequency in transcription units and gene-
dense regions, suggestive of selection against integration events within genes during 
long term passage. 
4.3 Material and Methods 
Vector transduction and preparation of bone marrow samples 
Vector design and transduction is described in (Negre et al., submitted).  
Briefly, clinical grade VSV-G pseudotyped lentiviral supernatant was produced by 
transient transfection of HEK293T cells with a 5-plasmid system.  Bone marrow cells 
were isolated from three-month-old female β-thalassemic mice, injected with 5-
fluoro-uracil (150 mg/kg) 4 days previously.  Nucleated cells were isolated and 
transduced for 24h, after which they were washed and resuspended in PBS.  400,000 
cells were injected via the retro-orbital sinus into each of five 6-month old recipient 
male β-thalassemic mice pre-treated with 4 daily doses of 20 mg/kg busulfan.  
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500,000 transduced cells from the transplant inoculum were grown in liquid culture 
for 11 days, and 30,000 plated in methylcellulose and cultured for 7 days in triplicate.  
Following culture, methylcellulose was dissolved, colonies harvested and genomic 
DNA extracted.  Recipient mice were sacrificed 9.2 months after transplantation and 
bone marrow harvested.  3 million cells from each mouse were used for immediate 
genomic DNA extraction, and 90,000 cells from each mouse were cultured in 
methylcellulose for 7 days before genomic DNA extraction. 
Isolation of integration site sequences 
Integration site isolation was performed by ligation-mediated PCR essentially 
as described previously [22, 24, 33, 34].  Each DNA sample (420-1000ng) was 
digested with MseI and NlaIII separately.  Linkers were ligated to the digested 
samples and samples treated with ApoI to limit amplification of the internal vector 
fragment downstream of the 5’ LTR.  Samples were then amplified by nested PCR 
and sequenced by 454 pyrosequencing at the University of Pennsylvania DNA 
sequencing center.  In order to sequence all amplicons in one sequencing run, PCR 
primers contained 8bp barcodes between the 454 sequencing primer and the region 
complementary to the LTR. 
Bioinformatic analysis 
Integration sites were determined to be authentic if the sequences began 
within 3bp of vector LTR ends, had a >98% match to the mouse genome (mm8 draft), 
and had a unique best hit when aligned to the mouse genome by BLAT.  All 
integration sequences will be deposited in GenBank upon acceptance of the paper for 
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publication.  Integration sites can be viewed on the UCSC browser at the following 
URL (http://genome.ucsc.edu/cgi-
bin/hgTracks?db=mm8&hgt.customText=http://microb230.med.upenn.edu/ucsc/Rone
n-BetaThalSites.bed.gz).  Three integration sites were found in sequences barcoded as 
more than one mouse and deduced to be likely due to crossover between samples 
during PCR (though transduced cells were pooled before transplantation, providing 
another candidate explanation).  The probable origin of each site was assigned based 
on sequence abundance and recovery in multiple samples from the same mouse, and 
excluded from analysis of the other mouse from which it was recovered.  For each 
experimental integration site three matched random control sites were 
computationally generated.  These sites were matched to the experimental sites in 
their distance to the nearest MseI or NlaIII site as appropriate. 
The RTCGD cancer gene database is available at http://rtcgd.ncifcrf.gov/.  
The expanded allOnco cancer genes list is described at 
http://microb230.med.upenn.edu/protocols/cancergenes.html. 
Enrichment of integration events relative to various genomic features was 
compared between datasets by Fisher’s exact (where stated) or by multiple regression 
models for integration intensity and a c-logit test for significance, as described in 
Berry et al. [35].  Receiver Operating Characteristic (ROC) analysis was used to 
represent the relationship between integration and various genomic features by a 
single numerical value [35], which was used to generate a colored heat map.  
Genomic features analyzed in Figure 4-3 are as follows. ‘In Refseq’ shows the 
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preference for integration within genes called by the Refseq gene call.  ‘Gene width’ 
shows the relationship with the length of the gene harboring the integration site.  
‘Intergene width’ shows the relationship with the length of the interval between 
genes.  Short genes and short intergene lengths are associated with gene-rich regions.  
‘Gene start distance’ shows the relationship to the distance to the nearest gene 5’ end. 
‘Gene boundary distance’ to the nearest gene 5’ or 3’ end. ‘Refseq count’ shows the 
relationship to the number of Refseq genes within a given window around each 
integration site (windows shown as 1Mb, 100kb etc). ‘Expression’ is gene activity, 
measured in MEFs using Affymetrix microarrays.  Genes were ranked for relative 
expression and the relationship is shown between integration and the expression level 
over given windows around ech site. ‘Top 1/2’ and ‘Top 1/16’ means only genes in 
the upper half or sixteenth were scored, respectively.  ‘CpG count’ is calculated 
analogously to ‘Refseq count’, counting the number of CpG islands in the window 
specified.  ‘CpG desnsity’ takes the number of CpG islands in the given window and 
divides by the number of base-pairs for a density measure.  ‘GC content’ denotes the 
percentage G/C residues in the sequence surrounding each integration site, in the 
window shown.  Analysis was carried out in R (http://www.r-project.org). 
Ingenuity Pathway Analysis software (http://www.ingenuity.com) was used to 
form networks based on gene lists assembled from the gene nearest to each 
integration site (Figure 4-2).  
miRNA predictions were annotated based on three online tools: miRbase 
(http://microrna.sanger.ac.uk/sequences/), TargetScan 
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(http://www.targetscan.org/mmu_50/) and miRDB 
(http://mirdb.org/miRDB/index.html) 
4.4 Results 
Isolation of integration sites from Lentiglobin-transduced bone marrow before and 
after transplantation 
Nucleated cells isolated from 5-fluorouracil-treated 3-month-old β-
thalassemic mice were transduced with the Lentiglobin vector for 24 hours. Cells 
were harvested at this time for integration site analysis (pre-transplantation samples).  
Before isolating genomic DNA, cells were subjected to liquid culture or 
methylcellulose culture. Methylcellulose culture selects for committed hematopoietic 
progenitor cells, which have sufficient replicative capacity to form colonies under the 
ex vivo culture conditions.  Culturing cells in this way therefore allowed us to study 
the integration sites of progenitor cells, and compare them to sites from total bone 
marrow, which also includes terminally differentiated cells.  Colonies derived from 
these progenitors were then isolated from the culture and genomic DNA extracted.  
500,000 pre-transplantation cells were cultured in liquid media for 11 days; 90,000 in 
methylcellulose-based media for 7 days, yielding about 2000 colonies from myeloid 
progenitors. Nine months after transplantation, bone marrow was also isolated for 
integration site analysis (post-transplantation). Post-transplantation cells were either 
cultured in methylcellulose as above, or DNA was extracted immediately. Three 
million bone marrow cells were used for immediate DNA extraction, and 90,000 bone 
118
marrow cells per mouse were cultured in methylcellulose, yielding about 50 colonies 
from myeloid progenitors per mouse. 
Vector integration sites were amplified from the genomic DNA as previously 
described [17].  Since this method relies on restriction digestion, which has been 
shown to introduce a significant recovery bias [17], samples were processed with two 
different restriction enzymes in parallel, MseI and NlaIII, in an attempt to maximize 
site recovery.  Vector-host junctions were sequenced by 454/Roche pyrosequencing, 
using 8bp barcodes in the primer to distinguish between sets run simultaneously. 
Table 4-1 summarizes the number of integration sites identified, pooling 
across the two restriction enzymes used on each sample.  Across all sets, we obtained 
a total of 31128 integrations passing quality control, representing 1162 unique sites 
over all sets.   The numbers of unique sites detected in each mouse ranged from 25-
28, providing an initial measure of the numbers of gene-corrected long-term 
repopulating cell clones present.  
However, the methods used for integration site recovery are unlikely to 
capture all integration sites, so we investigated methods for estimating the size of the 
full population.  Since two different enzymes were used to isolate integration sites 
from each sample, overlap between sites recovered by the two enzymes can be used 
to estimate the total number of sites using a capture-recapture approach.  Using the 
Lincoln-Petersen method [36], the number of unique sites estimated to be present in 
each mouse are 58, 48, 75, 140 and 48 for mice 31, 32, 33.1, 33.2 and 34 respectively 
(see supplementary table S4-1).  In another approach, based on a previous study 
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Table 4-1.  Integration site data sets used in this study.
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where six restriction enzymes were independently used to isolate integration sites 
from patients treated for X-SCID (Wang et al., submitted) we asked what proportion 
of all sites was recovered by MseI alone or NlaIII alone.  Based on that study, 
approximately 25% of all unique sites were isolated using either enzyme alone (data 
not shown).  According to this estimate, the numbers of unique sites in Table 4-1, 
which were isolated using both MseI and NlaIII, likely represent ~50% of the total 
sites present in the mice.  
The number of sites recovered per mouse was lower after methylcellulose 
culture than in samples that were not cultured in methylcellulose.  Ninety-thousand 
cells from each mouse were placed into methylcellulose culture, forming ~50 
colonies from which DNA was extracted, and 3 million cells were taken for 
immediate DNA extraction. Evidently plating and growth in methylcellulose selected 
out a subset of progenitor cells. 
Figure 4-1 shows the proportion of the most abundant integration sites 
identified in the bone marrow of each transplanted mouse, comparing sites from cells 
with and without methylcellulose culture.  Each site is classified by the gene it is 
either within or closest to, and the abundance of each site is displayed.  It can be seen 
that integration events post-transplantation were oligoclonal, with levels of clonal 
dominance varying from 40% to 70% in different mice. 
Integration is not enriched near genes associated with growth or oncogenesis 
 We next investigated the functional categories of the genes close to integration 
sites.  Insertional oncogenesis by retroviral vectors most commonly results from 
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Figure 4-1.  Integration site frequencies in individual mice, 9 months after 
Lentiglobin-transduced bone marrow transplantation.  Each integration site is 
labeled by the gene it falls within or the nearest gene, and represented by a different 
color.  The proportions of sequences recovered of each site are shown.  Sites recovered 
fewer than ten times were pooled and are displayed as ‘Low Freq’.
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activation of proto-oncogenes or, less commonly, inactivation of tumor-suppressors 
following nearby integration.  Thus, cells harboring integration sites close to growth-
control genes can have a selective advantage and become enriched in vivo.  We 
therefore asked whether integration sites post-transplantation showed evidence of 
such enrichment near genes associated with cell growth.  Table 4-2 shows the 
proportion of unique integration sites that lie within 50kb of a cancer gene, as defined 
by studies of insertional activation in mice (the RTCGD [37]).  Integration sites from 
all 5 mice were pooled in this analysis.  The proportion of sites in each data set is 
compared to the proportion pre-transplantation.  No statistically significant 
differences between sets were found by the Fisher’s exact test for proximity to cancer 
genes.  We also repeated these analyses with an extended list of cancer-related genes 
(the allOnco data set from 
http://microb230.med.upenn.edu/protocols/cancergenes.html).  This list is a 
compilation of several gene lists of cancer-associated genes from diverse vertebrates, 
in which all genes in any organism were mapped to their murine homologs (see 
Materials and Methods).  Results with this expanded list also did not show any 
statistically significant differences between sets (data not shown). 
A related question centered on whether the proportion of sites in each dataset 
where the closest gene was an RTCGD gene was increased after growth of cells in 
mice.  Integration sites were pooled over all mice for this analysis.  These values also 
did not differ between groups, or from random (Table 4-2). 
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Table 4-2.  Integration site frequency in the vicinity of oncogenes.
Integration Set
Sites in 
genes
Sites in 
exons
Percent in 
exons
Sites in same 
orientation as 
transcription
Percent same 
orientation as 
transcription
Pre-transplantation (liquid) 427 33 7.73 228 53.40
Pre-transplantation 
(methylcellulose)
219 13 5.94 112 51.14
Pre-transplantation (all) 641 46 7.18 336 52.42
Post-transplantation 
(uncultured)
83 5 6.02 39 46.99
Post-transplantation 
(methylcellulose)
23 0 0.00 13 56.52
Post-transplantation (all) 89 5 5.62 41 46.07
HIV MEFs 1745 106 6.07 860 49.28
Mouse lenti tumors 138 10 7.25 77 55.80
MRC pre-transplantation 
(liquid)
632 34 5.38 301 47.63
MRC pre-transplantation 
(methylcellulose)
370 23 6.22 193 52.16
MRC pre-transplantation 
(all)
997 56 5.62 490 49.15
MRC post-transplantation 
(uncultured)
172 4 2.33 78 45.35
MRC post-transplantation 
(methylcellulose)
75 4 5.33 35 46.67
MRC post-transplantation 
(all)
203 7 3.45 93 45.81
MRC HIV MEF 2492 127 5.10 1273 51.08
MRC mouse lenti tumors 247 13 5.26 133 53.85
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The above analysis did not take into account the frequency of recovery of 
different integration sites.  It could be imagined that an early indication of insertional 
activation would be the overrepresentation of integration sites close to genes involved 
in growth control.  We therefore asked whether there was a correlation between the 
frequency of recovery of a particular site and its proximity to genes in the RTCGD.  
Integration sites from each set were grouped into 3 bins of increasing recovery 
frequency, then the proportion of sites in each bin that fell within 50kb of an RTCGD 
calculated. No significant correlations between frequency of recovery and proximity 
to cancer genes were found in any data set (data not shown).  Thus these data provide 
no evidence of clonal expansion of cells bearing integration sites near growth control 
genes. 
We also used the Ingenuity network analysis software to study the functional 
categories of the genes close to integration sites.  Clustering of genes into networks 
related to growth control after growth in mice would be suggestive of selection for 
cells whose growth has been activated by vector integration. Post-transplantation sites 
were pooled across mice.  The highest-scoring networks based on integration sites 
pre-transplantation and post-transplantation are shown in Figure 4-2.  It can be seen 
that in both cases, genes with functions relating to growth control and cell death are 
represented, but growth in mice does not appear to have selected differentiallly for 
cells bearing integration sites near such genes. 
In the human β-Thal trial (Cavazzana-Calvo et al., submitted) outgrowth was 
detected of an integration site in the HMGA2 gene.  This was in the sense orientation 
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in the third intron of the gene, upstream of miRNA binding sites in the 3’UTR, 
leading to 3’ end substitution in the HMGA2 mRNA and potential release from post-
transcriptional repression.  We thus examined the most abundant sites in each mouse 
looking for outgrowth of integration sites lying in the sense orientation in the intron 
of a gene with predicted miRNA binding in the 3’ UTR.  Of the seven most abundant 
sites from five mice under the two culture conditions (Arap2 and Pam in mouse 31, 
uncultured and methylcellulose cultured respectively, Atp11b in mouse 32, Trim27 in 
mouse 33.1, BC004728 in mouse 33.2, Tmem164 and Ap3d1 in mouse 34), two sites 
(Pam and Tmem164) had these properties. Neither of these genes has been associated 
with oncogenesis.  Three of the seven were in the antisense orientation in introns, 
with miRNAs predicted in their 3’ UTR (Atp11b, BC004728, Ap3d1).  BC004728 
has been associated with metastasis [38, 39], but not tumorigenesis.  By comparison, 
of 963 unique pre-transplantation sites, 311 were in the sense orientation in an intron 
and 284 antisense in an intron.  We were thus unable to find any strong evidence 
associating clonal expansion with vector integration in the sense orientation within a 
growth control gene subject to miRNA regulation. 
Integration sites after growth of transduced cells in vivo or in methylcellulose culture 
are less frequently distributed in transcription units 
Lentiviral vectors show a preference for integration in particular genomic 
features, such as the bodies of transcription units and gene-rich regions of the genome 
[20, 22, 23, 35].  Figure 4-3 shows a heatmap representing the genomic distribution of 
integration sites in four types of samples – pre-transplantation and post-
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Figure 4-3.  Heat map illustrating genomic distribution of integration sites.  Favor-
ing or disfavoring of a genomic feature within a window around integration sites in each 
data set is represented as a colored tile.  The color is determined by ROC curve area 
comparing the density of the feature near experimental sites and matched random 
control sites.  See Materials and Methods for explanation of genomic features.  The 
p-value for the comparison with pre-transplantation liquid culture, determined by a 
logistic regression method that respects the pairing in the data (clogit), is overlaid on the 
heatmap tile (*p<0.05; **p<0.01; ***p<0.001).
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transplantation, each with and without methylcellulose culture.  For this analysis 
integration sites from all mice were pooled within a sample type.  For each genomic 
feature, favoring or disfavoring of integration in the feature compared to random is 
represented by red or blue coloring respectively.  The integration site distribution pre-
transplantation was consistent with previously published studies, with a favoring of 
transcription units and regions with high gene density, narrow genes, and high CpG 
island density.  However, post-transplantation and particularly following 
methylcellulose culture these trends weakened and in some cases reversed (asterisks 
represent statistically significant deviations from the pre-transplantation liquid culture 
dataset). 
Figure 4-4 shows a graphical representation of the frequency of integration in 
transcription units in each set.  It can be seen that while integration pre-
transplantation is significantly enriched in RefSeq transcription units, cell growth 
both in mice and in methylcellulose decreased the preference for provirus 
accumulation in transcription units.  67.7% of integration sites pre-transplantation 
without culture were found in transcription units.  In pre-transplantation cells cultured 
in methylcellulose, 64.8% of sites were in transcription units (p=0.0097 for the 
difference between the two).  Integration in post-transplantation cells in liquid culture 
was 52.5% in genes (p=0.014 for the difference with pre-transplantation uncultured 
cells) and in post-transplantation cells grown in methylcellulose culture 27.7% 
(p=1.59e-6 for the difference with pre-transplantation uncultured cells).  Integration 
in transcription units is thus below the level expected by chance after growth in mice 
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Figure 4-4.  Integration in transcription units.  The proportion of integration sites in 
each data set within or outside of transcription units are shown, normalized to matched 
random control sites (indicated by the horizontal line).  Significant differences from 
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and culture in methylcellulose, suggestive of selection against cells with integrated 
proviruses disrupting genes sensitive to dosage changes. 
We therefore asked whether any bias in the orientation of the provirus relative 
to transcription or integration in introns versus exons could be seen, since proviruses 
in different orientations may have different effects on host gene activity.  No 
statistically significant effects were seen (Table 4-3).  We thus conclude that provirus 
accumulation within transcription units was lower after prolonged growth, but that 
this was not associated with a bias in provirus orientation relative to the host 
transcription unit. 
4.5 Discussion 
The safety of lentiviral vectors for gene delivery has been a matter of intense 
interest in the gene therapy field, with extensive resources invested in optimizing 
vector design to minimize the risk of genotoxicity. Trials of gammaretroviral vectors 
in humans have led to adverse clinical events associated with clonal enrichment of 
integration sites near oncogenes and tumor-suppressors, but the three human trials of 
lentiviral gene therapy have not led to clinical adverse events to date.  In the third 
trial, involving transduction of hematopoietic stem cells for the treatment of β-
thalassemia, relative clonal dominance of cells containing a site in the proto-oncogene 
HMGA2 was observed (Cavazzana-Calvo et al., submitted), though the patient 
remains healthy.  Here, we present a study of integration by the lentiviral vector from 
this study in a mouse model of β-thalassemia. 
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Table 4-3.  Integration in gene features. 
Integration Set
Sites in 
genes
Sites in 
exons
Percent in 
exons
Sites in same 
orientation as 
transcription
Percent same 
orientation as 
transcription
Pre-transplantation (liquid) 427 33 7.73 228 53.40
Pre-transplantation 
(methylcellulose)
219 13 5.94 112 51.14
Pre-transplantation (all) 641 46 7.18 336 52.42
Post-transplantation 
(uncultured)
83 5 6.02 39 46.99
Post-transplantation 
(methylcellulose)
23 0 0.00 13 56.52
Post-transplantation (all) 89 5 5.62 41 46.07
HIV MEFs 1745 106 6.07 860 49.28
Mouse lenti tumors 138 10 7.25 77 55.80
MRC pre-transplantation 
(liquid)
632 34 5.38 301 47.63
MRC pre-transplantation 
(methylcellulose)
370 23 6.22 193 52.16
MRC pre-transplantation 
(all)
997 56 5.62 490 49.15
MRC post-transplantation 
(uncultured)
172 4 2.33 78 45.35
MRC post-transplantation 
(methylcellulose)
75 4 5.33 35 46.67
MRC post-transplantation 
(all)
203 7 3.45 93 45.81
MRC HIV MEF 2492 127 5.10 1273 51.08
MRC mouse lenti tumors 247 13 5.26 133 53.85
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We found that 9 months after transplantation integration sites in the bone 
marrow were oligoclonal.  The genes closest to integration sites did not show 
evidence of enrichment in growth-related functional categories relative to genes 
targeted in pre-transplantation sites.  Similarly, no enrichment of integration sites 
within 50kb of proto-oncogenes was found post-transplantation, and no relationship 
between the proximity of integration sites to oncogenes and site abundance. 
We estimated the numbers of gene-corrected progenitor cells in each mouse to 
be roughly 50-150 based on the numbers of unique integration sites recovered and 
upward corrections to account for sparse sampling.  It is of interest to compare these 
numbers to those expected based on estimates of stem cell proportions in bone 
marrow.  A total of 400,000 transduced cells were transplanted into each mouse.  It 
can be estimated that following treatment with 5-fluorouracil mouse bone marrow 
contains 1 in 10,000 stem cells [40-42].  In the transduction conducted in this study, 
an average of 70% of cells were transduced (Negre et al, submitted), so recovery of 
about 28 clones would be expected on average per mouse.  The numbers of clones per 
mouse estimated from vector marking were somewhat higher, ranging from ~50-150 
clones. We note that biases in recovery due to use of restriction enzyme cleavage 
would tend to inflate the estimates by artificially reducing the overlap between sets, 
possibly in part accounting for the differences.  However, the estimates from vector 
marking and stem cell counts were reasonably close, reinforcing the accuracy of 
estimates for both stem cell numbers and unique integration sites. 
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When initiating the integration site analysis, one question was whether we 
would see in mice the dominance of an integration site similar to that found in 
HMGA2 in the human trial.  In the human trial, integration of the Lentiglobin vector 
resulted in 3’ end substitution of the gene as well as an increase in the rate of 
transcription initiation.  The 3' end substitution removed a miRNA binding site in the 
3’ UTR. In mouse, HMGA2 has not been reported to be an oncogene.  However, 
there are other examples insertional activation by 3’ end substitution in the mouse. 
Pim1 and Gfi1 are oncogenes activated in T-cell lymphomas by substitution of their 
normal 3’UTRs, which contain miRNA binding sites [15, 43, 44].  Retroviral 
integration downstream of the oncogenes Fgf3 (int-2) [45] and c-myc  [46] has also 
been associated with oncogenic transformation.  We thus might have seen enrichment 
of integration sites near these genes following transplantation into mice, but this was 
not the case.  The closest site to Pim1 was 80,427bp upstream of the 5’ end in an 
intergenic region, the closest to Fgf3 was over 3Mb upstream and lying within 
another gene, the closest to c-myc was over 10Mb upstream in an intergenic region.   
Of the seven most abundant sites recovered from the five mice, none were strong 
candidates for activation and clonal skewing by 3' end substitution of known growth 
control genes. Overall, the results in mice did not detectably recapitulate the clonal 
skewing associated with insertion in the HMGA2 third intron seen in the human β-
thalassemia trial. 
The main detectable difference in integration site distribution between pre-
transplantation and post-transplantation samples was an effect on the frequency of 
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provirus accumulation in transcription units.  We found that growth of transduced 
cells in mice or, to a greater extent, in methylcellulose was associated with a decrease 
in the favoring of integration in transcription units.  We carried out a meta-analysis of 
previously published integration site datasets that have compared the proportion of 
lentiviral integration sites in transcription units pre-transplantation and post-
transplantation into mice or humans.  Shown in Table 4-4 are data from three 
published studies where cells were transduced by a lentiviral vector and transplanted 
into mice or humans, and vector integration sites were analyzed before and after 
transplantation. We found that two of the three studies (one to treat Wiskott-Aldrich 
syndrome in mice [47], and one to treat HIV in humans [27]) showed a decrease in 
the frequency of integration in transcription units after transplantation, though only 
one difference was statistically significant (Table 4-4). Evidence of selection against 
other retroviral elements integrated in genes can also be found.  Reduced preference 
for integration in transcription units has been observed in patients chronically infected 
with HTLV, compared with ex vivo infections [48].  Similarly, it has been reported 
that evolutionarily older endogenous retroviruses are found less frequently in 
transcription units, in both mouse and human [49-53], likely reflecting selection 
against cells bearing integrated proviruses in transcription units.  A potential 
explanation for our results would be that integration of lentiviral vectors into 
transcription units disrupted expression of the gene, and that this more often leads to a 
fitness cost for that cell than a fitness advantage.  The effect could be at the 
transcriptional level, involving a change in mRNA levels, or via production of 
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Table 4-4.  Frequency of integration in transcription units in published studies. 
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abnormal proteins.  Maruggi et al. [12] showed that lentiviral vectors caused 
transcriptional deregulation (both up- and down-regulation) of genes within 200kb of 
integration events.  The frequency of this effect for lentiviral vectors was lower than 
for gammaretroviral, and the nature of the internal promoter appeared to be important.  
Thus effects on gene dosage may have resulted in some cells having a growth 
disadvantage that became evident after long-term proliferation. 
In summary, our data show that gene transfer with the Lentiglobin vector used 
in the human clinical trial was not associated with clonal skewing during 
reconstitution of mice.  However, our observations are consistent with a model in 
which the integration of a lentiviral vector in or near genes influenced the target cell 
via effects on gene activity.  Surprisingly, however, it seems that the most common 
consequence in this study was a growth disadvantage, since cells with integrations 
within genes appear to have been selected against during growth.  Following the 
findings in the human β-thalassemia trial, the results of this study are reassuring, but 
suggest more detailed analysis of the effects of integrating lentiviral vectors on 
cellular gene expression and associated fitness costs may be warranted. 
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CHAPTER 5 – NOVEL HOST FACTORS IN HIV INTEGRATION SITE 
SELECTION 
 
5.1 Abstract  
Three genome-wide siRNA screens have recently been published identifying 
host factors necessary for HIV infection. There has been much interest in 
characterizing in more detail the effects of identified factors and possible mechanisms 
of action.  We analyzed a number of these host factors, and additional candidate host 
factors identified by other means, that appear to act at the integration steps of the 
replication cycle.  In previous studies, LEDGF/p75 was found to be important for 
efficient infection, and to act as a targeting factor directing HIV integration to active 
transcription units.  We used 454 sequencing of integration sites to ask whether any 
of the newly identified factors that are important for efficient integration also 
influence integration targeting.  We carried out bioinformatic analysis of HIV 
integration sites isolated from cells treated with siRNAs against PRPF38A, MAP4 
and SETD2.  These data suggest integration site selection is altered when under these 
conditions, though whether these effects are due to depletion of these factors or a 
more indirect mechanism is unclear.  Common themes emerge from the analysis of 
these knockdowns, with diminished enrichment of integration sites in transcription 
units and gene-rich regions compared with integration in control cells.  Surprisingly, 
the patterns differ from that observed in integration sites from LEDGF/p75-depleted 
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cells, suggesting that LEDGF/p75 may not be the only host factor responsible for the 
characteristic genomic distribution of HIV integration sites. 
5.2 Introduction 
Integration is a necessary step of the HIV lifecycle, whereby the reverse-
transcribed viral genome becomes covalently joined to the genome of the infected 
cell.  In vitro, the viral protein integrase (IN) is sufficient to mediate the integration of 
donor into target DNA [1-3], and the reaction shows weak specificity for target 
sequence [4-6].  However, in the cell, IN catalysis takes place in the context of a large 
nucleoprotein complex, the pre-integration complex (PIC), into host chromatin in the 
nuclear environment.  A number of host proteins have been shown to interact with the 
PIC [7-11] with potential roles in infection.  Furthermore, integration occurs in a non-
random distribution in the host genome, which is not accounted for by IN’s weak 
sequence preference [12-14].  Integration site preferences vary between retroviral 
classes, with lentiviruses such as HIV showing a preference for active transcription 
units and gammaretroviruses such as MLV showing a preference for CpG islands and 
gene 5’ ends [13, 14].  The fact that these preferences track with retroviral genus but 
are not seen in in vitro integration by purified IN or PICs suggests that viral 
components of the PIC likely interact with host proteins or chromatin structure to 
influence the distribution of integration events in the genome. 
Indeed, this prediction has been confirmed by studies with the host protein 
LEDGF/p75 [15, 16].  LEDGF/p75 was identified as a binding partner of lentiviral IN 
[11, 17], and was shown to mediate IN chromatin binding [18, 19], protect IN from 
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proteasomal degradation [20] and stimulate IN in vitro activity [11].  Human and 
mouse models of stringent LEDGF/p75 depletion have shown that LEDGF/p75 is a 
necessary integration factor: in a knockdown or knockout integration by HIV or a 
related lentivirus EIAV were blocked 5- to 30-fold [21-23].  Furthermore, integration 
in the absence of LEDGF/p75 showed a different distribution around the genome 
from that in wild-type cells.  In LEDGF/p75-depleted cells, the preference for 
integration in transcription units was diminished [22-24].  Additionally, the GC 
content of the sequence around integration sites was observed to increase and 
integration in CpG islands became favored in the absence of LEDGF/p75.  This has 
led to a tethering model of integration placement, whereby a chromatin-bound host 
factor interacts with a viral component of the PIC and tethers integration events to the 
regions around its binding sites.  In the case of LEDGF/p75, this model has been 
further confirmed through the demonstration of integration retargeting by expression 
of fusion proteins containing the IN-binding portion of LEDGF/p75 fused to 
alternative DNA binding domains (as described in Chapter 3) [25, 26]. 
However, studies of LEDGF/p75 in integration targeting leave some open 
questions.  Firstly, LEDGF/p75’s cellular role, binding partners and mechanism of 
chromatin interaction remain partially understood, raising the question of whether 
other factors might participate in this tethering mechanism.  Secondly, while 
depletion of LEDGF/p75 has marked and significant effects on the distribution of 
lentiviral integration sites, sites are not randomly distributed in its absence, 
suggesting other factors may contribute. 
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We sought to investigate alternative integration site determinants.  In 
considering candidate factors we reasoned that novel tethering factors would likely 
phenocopy the known tethering factor, LEDGF/p75.  We therefore focused initially 
on host proteins whose depletion from the cell, like LEDGF/p75, led to an infection 
block at the step of integration, and analysed the distribution of HIV vector 
integration sites in cells depleted for these factors.  A large number of candidate 
factors was provided in the form of hits from a recent genome-wide siRNA screen by 
König et al. that identified factors necessary for HIV infection [27].  We report here 
integration site data from cells depleted by siRNA knockdown for two factors 
identified as hits by König et al.  PRPF38A is a splicing factor, annotated in the 
human genome by its homology to the yeast protein PRP38, which is required for 
spliceosome maturation [28].  It was identified as a factor necessary for integration in 
the König et al. screen.  MAP4 is a microtubule-associated protein involved in 
microtubule assembly and cell cycle progression [29, 30].  It was independently 
identified in two genome-wide siRNA screens [27, 31] and has also been reported to 
interact with LEDGF/p75 by yeast-two-hybrid (Sumit Chanda, personal 
communication).  We additionally investigated SETD2/HYPB, a histone methyl-
transferase that methylated histone 3 on lysine 36 [32, 33], a modification that is 
found in the bodies of transcription units and closely follows the distribution of HIV 
integration sites in the genome [26].  SETD2 recruits to active genes several other 
proteins involved in mRNA processing and export [34].  One of these is IWS1, which 
has been shown to bind LEDGF/p75 (Katherine Jones, personal communication).  
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Knockdown of SETD2 led to a reduction in HIV infection efficiency, though the gene 
had not been identified as a hit in genome-wide siRNA screens.  We found that 
depletion of PRPF38A, SETD2 and MAP4 resulted in an altered distribution of 
integration sites, and common themes emerged from the changes: knockdown of all 
genes led to a slight reduction in the frequency of integration in transcription units 
and a shift of integration to less gene-dense and GC-rich regions.  In data not shown, 
from Troy Brady in the lab, knockdown of nuclear import factors TNPO3 and 
ANAPC2 showed similar effects.  In order to rule out off-target effects, we expressed 
an siRNA-resistant form of SETD2, and found that the infection block induced by 
siRNA-treatment was not rescued.  Thus, the significance of these effects is unclear.  
Possible interpretations are discussed. 
5.3 Materials and Methods 
Cell culture and transfection 
293T cells were cultured in Dulbecco’s Modified Eagle Medium with 
Glutamax (Invitrogen), 10% FBS (Sigma) and 50µg/ml gentamycin (Sigma).  For 
siRNA treatment, cells were reverse-transfected.  Cells were seeded in 12-well plate 
format, 100,000 cells to a well in antibiotic-free DMEM with 10% FBS.  siRNAs 
were incubated with Optimem serum-free medium (Invitrogen) and RNAiMax 
transfection reagent (Invitrogen), as per manufacturer’s instructions, and added to the 
cells at the time of seeding.  37.6pmol siRNA and 1.88ul RNAiMax were used per 
well.  For co-transfection of siRNAs and rescue plasmids, reverse transfection was 
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carried out in the same way, using 37.6pmol siRNA, 500ng plasmid DNA and 1.88ul 
RNAiMax were used per well.   
siRNAs used 
 siRNAs against SETD2 were from Qiagen (siRNA 1 in the text is HYPB_1, 
catalog number SI00103292) and Ambion (siRNA 2 in the text has sequence 
GUGAAGGAGUAUGCACGAAtt). siRNAs against PRPF38A and MAP4 were 
from Qiagen (catalog numbers SI00395808, SI00395815, SI00627809, SI00627816).  
The control luciferase siRNA was from Qiagen (GL2, catalog number 1022070). 
siRNA-resistant cDNA cloning 
 SETD2 cDNA was purchased from Open Biosystems (clone ID 40125715).  
Site-directed mutagenesis was performed using the Quikchange kit (Stratagene).  
Two sets of 7 synonymous mutations were introduced separately, to each of the 
regions targeted by the siRNAs used.  The coding sequence was then amplified to 
incorporate restriction enzyme sites (primers kr225, 
AGTCCAagatctagaGAAAGAAGAGGCAAGTATTCTTC and kr227, 
agtccaGTCGACctcgagTCACTCTAATTCAGTGTCCTCTTTGG).  The amplicon 
was digested with BglII and SalI and inserted into a plasmid containing a 3xFlag tag, 
digested with BamHI and SalI.  Flag-tagged SETD2 was then cut out using AgeI and 
SalI and ligated into a vector based on the MLV-based CMV-promoter-driven 
expression plasmid pLNCX (kind gift of Paul Bates), previously engineered to carry a 
WPRE. 
Viral particle production and infection 
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 VSV-G pseudotyped HIV vector particles were produced by Lipofectamine 
transfection of 293T cells with p156RRLsin-PPTCMVGFPWPRE [35], the 
packaging construct pCMVdeltaR9 [36], and the vesicular stomatitis virus G-
producing pMD.G construct.  Viral supernatant was harvested 38 hours after 
transfection, filtered through 0.22µm filters, concentrated by filtration through a 
Centricon, treated with DNase I, and stored frozen at -80°C.  HIV titer was quantified 
by p24 ELISA. 
 Cells were infected 48h after transfection: medium from the transfection was 
removed and replaced with DMEM + 10% FBS and 50µg/ml gentamycin containing 
50-100ng p24 VSV-G pseudotyped virus.  Infection mix was left on the cells 
overnight and then replaced with fresh medium.  Infection was allowed to proceed for 
48h, after which cells were trypsinized and harvested for FACS, proviral Q-PCR, 
gene expression analysis by Q-RT-PCR, or integration site analysis. 
Q-PCR  
 For quantification of integrated proviruses, a two-step Alu-PCR assay was 
used, described in reference [37].  This consists of an intitial round of amplification 
from genomic Alu repeats to viral Gag sequence, followed by Q-PCR specific for an 
amplicon in R-U5 with molecular beacon probes on an Applied Biosystems 7500 Fast 
Realtime PCR instrument.  Samples were run in triplicate. 
 For gene expression analysis, total RNA was extracted from cells using the 
Illustra RNAspin kit (GE healthcare).  50ng RNA from each sample was reverse 
transcribed using the High Capacity RNA to cDNA kit (Applied Biosystems).  cDNA 
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was diluted 100-fold and QPCR performed in triplicate on each sample with 
commercial primers and Taqman MGB FAM-labeled probes (Applied Biosystems, 
SETD2 assay ID: Hs00383438_m1) and Taqman Fast Universal Mastermix (Applied 
Biosystems, catalog number 4352042).  Q-PCR was also performed on all samples 
with GAPDH primers and probe (Applied Biosystems catalog number: 402869).  
SETD2 expression was calculated by the ΔΔCt method.  An Applied Biosystems 
7500 Fast Realtime PCR instrument was used. 
Western blot 
 Cell pellets were lysed in 1X RIPA buffer with protease inhibitors (Roche, 
catalog number 11697498001), lysates mixed with SDS buffer and subjected to SDS 
polyacrylamide gel electrophoresis.  Flag was detected using anti-Flag M2-peroxidase 
conjugated (Sigma, catalog number A8592).  β-tubulin was used as a loading control 
(Abcam ab21058).  SETD2 detection with Abcam antibody ab69836 was attempted 
but gave only non-specific bands.  Visualization was by chemiluminesence, using 
Supersignal West Chemiluminescent substrate (Pierce, catalog number PI34080). 
Integration site analysis 
 Integration sites were isolated and sequenced by ligation-mediated PCR 
essentially as described previously [38].  Genomic DNA was extracted from infected 
cells using the Qiagen DNeasy tissue extraction kit. Up to 2µg of DNA from each 
infection was digested overnight using MseI. This was followed by digestion to 
prevent amplification of internal viral fragments (from the 5’ LTR) and plasmid 
backbone with SacI and DpnI.  Linkers were then ligated onto digested products 
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(oligonucleotide sequences listed below) and nested PCR performed from ligation 
products.  Nested PCR primers contained 8 nt barcode sequences between the 
sequencing primer and LTR-binding portions.  These enabled pooling of all PCR 
products into one sequencing reaction and subsequent separation of sequences by 
decoding the barcodes. Samples were sequenced on the Roche 454 GS-FLX 
instrument at the University of Pennsylvania. 
 Integration sites were judged to be authentic if the sequences had a best unique 
hit when aligned to the murine (mm8 draft) using BLAT, and the alignment began 
within 3bp of the viral LTR end and had >98% sequence identity.  Detailed statistical 
methods are described in [6].  
 To control for possible biases in isolating integration sites due to restriction 
enzyme sequence distribution, three or ten matched random controls were 
computationally generated for each experimental integration site that were the same 
distance from the closest MseI restriction site as the experimental site. 
 Integration site counts in various genomic annotations were compared with 
matched random controls by the Fisher’s exact test.  Additionally, multiple regression 
models for integration intensity were applied, as described in [6]. Analysis was 
carried out in the R statistical package (http://www.r-project.org). 
5.4 Results 
HIV infection is inhibited by knockdown of MAP4, PRPF38A and SETD2 
 König and colleagues recently conducted a genome-wide siRNA screen to 
identify human genes necessary for HIV infection [27].  293T cells were treated with 
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siRNAs against a panel of around 20,000 genes and hits identified as genes that, when 
knocked down by two or more independent siRNAs, led to a block in HIV reporter 
gene expression.  Hits were prioritized for downstream analysis based on several lines 
of evidence such as cellular toxicity of knockdown, co-expression with CD4, CXCR4 
and CCR5, and evidence of interaction with HIV proteins.  For genes passing these 
filters, the infection block induced by siRNA treatment was placed in a stage of the 
viral lifecycle.  We focused on hits from the screen whose effects had been mapped to 
the integration step of the lifecycle.  MAP4, a microtubule associated protein, and 
PRPF38A, a splicing factor, were two such factors.  Additionally, we investigated the 
potential role of SETD2/HYPB, a histone methyltransferase suggested to interact 
with a LEDGF/p75-binding protein. 
 293T cells were treated with siRNAs directed against PRPF38A, MAP4, 
SETD2 or luciferase as a control, and 48h later infected with VSV-G pseudotyped 
GFP-expressing HIV.  Cells were harvested 48h later for FACS analysis to measure 
infection efficiency, and for integration site analysis.  Table 5-1 summarizes the genes 
studied and their effects on HIV infection.  In agreement with the results of König et 
al., knockdown of both MAP4 and PRPF38A caused a decrease in susceptibility to 
HIV infection (on average 1.67-fold and 1.35-fold respectively).  Knockdown of 
SETD2 with two different siRNAs also led to a decrease in HIV infection efficiency 
(on average a 1.51-fold decrease in GFP expression). 
HIV integration site selection is modified by knockdown of PRPF38A, SETD2 and 
MAP4 
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Table 5-1.  Effects of genes studied on HIV infection efficiency.  293T cells were 
transfected with the siRNAs shown 48h prior to infection with VSV-G pseudotyped 
GFP-expressing HIV.  The percentage of cells expressing GFP was determined by 
FACS 48h post-infection.  Numbers are expressed as fold reduction of this value 
compared with control-infected cells. 
Gene Information Known functions siRNA used
Fold Reduction 
HIV Infection 
(FACS)
Control 
(luciferase)
GL2 1.00
PRPF38A_2 1.67
PRPF38A_3 nd
MAP4_3 1.20
MAP4_4 1.49
SETD2_1 1.61
SETD2_2 1.40
SETD2
Binding partner of IWS1, 
which interacts with 
LEDGF/p75
H3K36 
methyltransferase
PRPF38A
Identified in siRNA screen 
(integration factor)
Spliceosome
MAP4
Identified in siRNA screen 
(integration factor); binds 
LEDGF/p75 by Y2H.
Microtubule 
binding
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 Having confirmed that knockdown of MAP4, PRPF38A and SETD2 reduced 
the efficiency of HIV infection, we examined the effect of these potential cofactors on 
integration site selection. Integration site amplification was carried out essentially as 
described previously [38], sites aligned to the human genome and nearby genomic 
features annotated.  The number of integration sites analyzed from each siRNA 
treatment and summaries of genomic features near these sites are shown in Table 5-2.  
For reference, a dataset from 293Ts stably knocked down for LEDGF/p75 (the siLL 
cells from [24]) is shown, as well as a set of computationally generated random 
controls (see methods).  One of the goals of this study was to identify factors that may 
participate in LEDGF/p75 tethering.  Depletion of factors that cooperate with 
LEDGF/p75 would be expected to alter integration targeting in the same way as 
LEDGF/p75 depletion does.  We therefore started by examining the preference for 
integration in genes.  Table 5-2 summarizes the proportions of integration sites falling 
in transcription units from cells treated with various siRNAs. Consistent with 
previous data, HIV integration from control cells was favored in the bodies of 
transcription units, with 72.1% of sites falling in RefSeq genes.[12], and this 
preference was reduced in LEDGF/p75 knockdown cells [24].  Integration sites from 
cells treated with siRNAs against MAP4, PRPF38A and SETD2 all showed slight 
decreases in the frequency of integration in transcription units, with MAP4 
knockdown showing the weakest effect (67.6% and 65.7% in genes depending on the 
siRNA used), PRPF38A intermediate (61.8% and 62.7% in genes) and SETD2 the 
strongest effect (59.5% in genes).  Comparing these proportions to those in control 
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Table 5-2.  Effect of cofactor knockdown on the genomic distribution of HIV 
integration sites.  Cells were transfected with the siRNAs shown and 48h later 
infected with VSV-G pseudotyped HIV.  Integration sites were isolated 48h post-
infection, aligned onto the genome and annotated with respect to the genomic features 
shown.  Asterisks denote statistical significance as determined by a c-logit test 
applied to a logistic regression model, or Mann-Whitney U test as appropriate. 
* p<0.05, ** p<0.01, ***p<0.0001. 
Data set
Integration 
sites
% in 
genes
Average 
GC % in 
5kb
Average 
number genes in 
1Mb
GL2 4152 72.1 40.5 20.2
PRPF38A_2 1591 61.8*** 38.0*** 13.8***
PRPF38A_3 721 62.7** 38.7*** 15.1***
MAP4_3 3730 67.6 39.4*** 17.5***
MAP4_4 3418 65.7** 39.9*** 17.9***
SETD2_1 2271 59.5*** 39.1*** 17.0***
LEDGF_siLL 468 59.2*** 41.8*** 18.9
Random 12954 35.6*** 39.7*** 10.1***
155
cells achieved statistical significance, but as shown in Table 5-2, the changes were of 
smaller magnitude than those seen in LEDGF/p75-depleted cells.  It should also be 
noted that the LEDGF/p75 knockdown shown here is a partial knockdown – more 
stringently depleted models have been made in other cell types that show a greater 
reduction in the frequency of integration in genes (see Chapter 2). 
 Another effect observed in LEDGF/p75-depleted cells is a shift of integration 
sites into regions of higher GC content [22-24].  We therefore wondered whether 
knockdown of these factors might show the same effect, supporting the idea that these 
factors are part of the LEDGF/p75 machinery.  Table 5-2 shows the average GC 
content of 5kb regions surrounding integration sites isolated from control and siRNA-
treated cells.  It can be seen that the GC content of regions surrounding integration 
sites from different treatments varied, with LEDGF/p75 knockdown showing an 
increase in GC content as previously reported.  However all other knockdowns 
showed decreases in the average GC content.  While these differences did achieve 
statistical significance when compared to control cells, the magnitude of the changes 
was very small (ranging from 41.8% GC in LEDGF/p75 knockdown cells to 38.0% in 
PRPF38A knockdown cells).  A more sensitive way to analyze this type of data than 
to examine the average value surrounding each site is to compare the distributions of 
values around sites from two conditions. Since siRNAs targeted against the same 
gene showed similar effects, we pooled integration sites from different siRNAs to 
generate such graphs.  Figure 5-1 shows this analysis.  The GC content in the 5kb 
surrounding each integration site was calculated, then sites from control and treated 
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Figure 5-1. The effect of cofactor knockdown on integration with respect to GC 
content.  HIV vector integration sites from cells treated with siRNAs against each 
of the genes shown were isolated and mapped onto the genome.  The GC content in 
a 5kb window around each site was calculated. Sites from control and knockdown 
sets were combined and split into ten bins of increasing GC content with equal 
numbers of sites in each bin.  The proportion of each set found in each bin is shown. 
P values were determined using the likelihood ratio statistic for the logistic regres-
sion model.  LEDGF/p75 knockdown data are from stable knockdown 293T cells as 
in [19].
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cells combined and broken into ten bins of increasing GC content.  The proportion of 
sites from each treatment found in each bin is displayed.  It can be seen that, whereas 
LEDGF/p75 depletion led to an increase in the GC content around sites, knockdown 
of PRPF38A, SETD2 and, to a lesser extent, MAP4, had the opposite effect.  Though 
these changes are all slight, they are statistically significant, and the difference 
between LEDGF/p75 knockdown and the other knockdowns argues against the idea 
that knockdown of the genes studied here disrupts the same complex as LEDGF/p75 
depletion. 
 A number of genomic features tend to correlate in the genome, for example 
regions with a high GC content tend to also be gene-rich.  We therefore analyzed the 
gene density of 1Mb windows surrounding integration sites from cells treated with 
different siRNAs.  The results are summarized in Table 5-2 and shown graphically in 
Figure 5-2, analyzed in the same way as GC content in Figure 5-1.  In agreement with 
the effect on GC content, we observed that knockdown of PRPF38A, SETD2 and 
MAP4 led to integration sites lying in less gene-dense regions.  LEDGF/p75 
knockdown, however, had no effect on gene density surrounding integration sites, 
again arguing against the idea that any of the novel factors tested here participate in 
LEDGF/p75-mediated integration tethering. 
The effects of SETD2 knockdown may be off-target 
 siRNA treatment is known to cause off-target effects, such as knockdown of 
additional genes with sequence similarity to the target gene, or induction of an 
interferon response [39].  Using two siRNAs targeted against each gene increased our 
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Figure 5-2. The effect of cofactor knockdown on integration with respect to 
gene density.  HIV vector integration sites from cells treated with siRNAs against 
each of the genes shown were isolated and mapped onto the genome.  The number 
of RefSeq genes in a 1Mb window around each site was calculated. Sites from 
control and knockdown sets were combined and split into ten bins of increasing 
gene density with equal numbers of sites in each bin.  The proportion of each set 
found in each bin is shown. P values were determined using the likelihood ratio 
statistic for the logistic regression model.  LEDGF/p75 knockdown data are from 
stable knockdown 293T cells as in [19].
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confidence that the effects on infection and integration site selection were 
authentically due to depletion of the proteins of interest.  However, we sought to 
confirm the specificity of the effect by delivering to knockdown cells an siRNA-
resistant clone of the gene of interest, and testing for the block to infection.  This 
allows expression of the protein to be rescued, but any potential off-target effects 
induced by the siRNA treatment to remain. 
 cDNAs of SETD2 were engineered to contain 7 synonymous mutations in the 
21bp recognition sequences of the two siRNAs that inhibited HIV infection.  These 
mutated cDNAs were flag-tagged for ease of detection and cloned into a mammalian 
expression vector containing a CMV promoter.  293T cells were cotransfected with 
control or SETD2 siRNAs and the rescue constructs, or empty vector as a control.  
48h later, cells were infected as before, and 48h after infection cells were harvested.  
SETD2 transcription was measured by quantitative RT-PCR and expression of the 
flag-tagged rescue constructs was measured by Western blot.  Figure 5-3A and B 
shows that the rescue constructs were successfully expressed at the level of RNA and 
protein.  The susceptibility of cells to HIV infection was determined by measuring 
integrated viral copies by quantitative PCR.  These results are displayed in Figure 5-
3C.  Cells transfected with the control siRNA and rescue constructs showed slight 
increases in infection efficiency compared with control cells, indicating that 
overexpression of SETD2 was not toxic or inhibitory to infection.  Cells treated with 
the two siRNAs directed against SETD2 showed a roughly 3-fold reduction in the 
number of integrated proviruses.  Cotransfection of rescue constructs did not lift this 
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Figure 5-3.  The infection block induced by SETD2 siRNA treatment is not 
rescued by overexpression of siRNA-resistant SETD2 cDNA.  A. Expression of 
SETD2 RNA, measured by Q-RT-PCR.  Values shown are means of two biological 
replicates, plus and minus standard deviation. B. Representative Western blot for 
Flag-tagged construct expression. C. Integrated HIV proviruses, measured by Q-PCR. 
Values shown are means of two biological replicates, plus standard deviation.
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infection block.  It remains possible that the Flag-tagged constructs used here were 
misfolded, Myc- and Flag-tagged SETD2 or portions of SETD2 have been used with 
apparent success in previous publications [40].  This result therefore fails to rule out 
the possibility that off-target effects are responsible for the inhibition of HIV 
infection by SETD2 knockdown. 
Knockdown of other genes involved in HIV integration and nuclear import shows 
similar results 
Experiments conducted by Troy Brady and Karen Ocwieja in the lab (data not 
shown) have examined the effect of other knockdowns on HIV integration site 
selection.  Two more hits were selected from genes identified in the König siRNA 
screen. ANAPC2 is another gene identified in the screen as a factor that when 
knocked down reduced the level of HIV integration.  It is a component of the 
anaphase promoting complex involved in cell cycle regulation [41].  TNPO3 
(transportin SR2) is a member of the karyopherin β family of proteins that shuttles 
between the nucleus and cytoplasm and is involved in nuclear import of proteins such 
as SR splicing factors [42].  Knockdown of TNPO3 was shown to inhibit HIV 
infection at the stage of nuclear import in two recent genome-wide siRNA screens 
[27, 31].  It was also independently identified as interacting with HIV integrase [10] 
and confirmed to be required for nuclear import, though subsequent studies of its role 
in infection have suggested the involvement of the capsid protein [43]. 
 Knockdown of ANAPC2 and TNPO3 in 293T cells, infection and integration 
site analysis was conducted as described above for SETD2, PRPF38A and MAP4.  
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The effects of knockdown of ANAPC2 and TNPO3 were found to be similar to those 
reported here.  ANAPC2 and TNPO3 knockdown did not show significant effects on 
the frequency of integration within transcription units, but did lead to a reduction in 
the GC content and gene density of chromatin surrounding HIV integration sites. 
 Add-back experiments, as described here for SETD2, were completed for both 
TNPO3 and ANAPC2.  In those cases, rescuing gene expression did mediate at least a 
partial rescue of the infectivity and integration site effect. 
5.5 Discussion 
 Much attention has recently been paid to host factors necessary for HIV 
infection.  Studying interactions between host and viral proteins is valuable in 
furthering our understanding of the HIV lifecycle and identifying potential 
therapeutic targets.  One aspect of the lifecycle where host factors are known to be 
important is integration and the targeting of certain genomic features by integration 
events: LEDGF/p75 is required for efficient integration and determining much of the 
preference of lentiviruses for integration in transcription units.  However, other 
factors may also be important, either as part of the LEDGF/p75 machinery, or as a 
parallel system still active in its absence. 
In this study we investigated whether host proteins whose knockdown inhibits 
HIV infection at the step of integration also have an impact on integration site 
selection.  We tested this by treating cells with siRNAs directed against three factors, 
PRPF38A, MAP4 and SETD2 whose knockdown reduced HIV infection efficiency.  
Small but statistically significant changes in the genomic distribution of integration 
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sites were observed, with broadly similar effects resulting from the three 
knockdowns: the frequency of integration in genes was slightly reduced, the GC 
content of 5kb windows around integration sites was reduced, and the gene density of 
1Mb windows around integration sites was reduced. 
 The significance of these findings remains unclear.  Importantly, the changes 
induced by knockdown of these proteins differ from the changes induced by 
LEDGF/p75 depletion.  This argues against the idea that the factors tested were 
LEDGF/p75 cofactors.  A number of interpretations could therefore be imagined. The 
first is that the proteins studied in this work all assist in the nuclear trafficking of the 
pre-integration complex, enabling nuclear import (eg. TNPO3) or integration (eg. 
PRPF38A, MAP4, SETD2, ANAPC2).  This is known to be true for TNPO3, and 
suggested, though not demonstrated, for MAP4 and SETD2, by their purported 
interaction with LEDGF/p75 or its binding partners.  Disruption of this trafficking 
might alter the placement of integration events in chromatin.  Chromatin is known to 
be organized into higher order structures in the nucleus, with characteristic 
distributions of particular genomic regions [44].  Perhaps disruption of nuclear 
trafficking pathways, by depletion of any of the above factors, misdirects PICs into 
less gene-dense, GC-rich regions of the genome. 
However, questions remain about off-target effects.  The infection block 
induced by SETD2 siRNAs could not be rescued by siRNA-resistant cDNA 
expression, and the integration site effects observed in this system were very similar 
to those observed in others.  Another possible interpretation of the data therefore 
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remains: that siRNA treatment resulted in knockdown of some unintended factor or 
induced an innate immune or stress response.  In this situation, some other indirectly 
modulated factor could be the true mediator of integration targeting in gene-dense 
regions.  Relatedly, such off-target effects could alter cellular chromatin structure to 
make gene-dense regions less accessible.  The induction of an interferon response 
could be studied by assaying the expression of interferon-inducible genes following 
siRNA treatment.  Similarly, cells could be treated with interferon-β prior to infection 
to see if the integration site selection was redistributed as reported here. 
A related confounding effect could be that on-target depletion of these 
proteins, though not affecting HIV infection directly, results in global gene 
expression changes that then alter integration targeting, by modulating some tethering 
factor or causing changes in chromatin accessibility. 
It should be noted that similar effects to those reported here have been 
observed when comparing integration site selection in other settings.  Comparing 
dividing and growth-arrested IMR90 fibroblasts, Ciuffi et al. [45] found that HIV 
integration sites from dividing cells were in less gene-dense regions than growth 
arrested cells.  This result could lend support to the idea that passage of the PIC 
through the nuclear pore, which would be necessary in non-cycling cells, may have 
an impact on the distribution of sites in chromatin.  However, the opposite effect was 
reported by Brady et al., who showed that integration sites in activated T-cells were 
in more gene-dense and GC-rich regions than integration sites in resting T-cells, 
which divide less [46].  Furthermore, Chapter 6 of this dissertation presents data that 
165
pharmacological inhibition of integrase strand transfer also leads to similar effects on 
HIV integration site selection. 
In all, these data suggest that HIV integration targeting may be shaped by 
variables in addition to LEDGF/p75 expression.  Whether the proteins described here 
participate in this process, or their knockdown affected integration in some other way 
requires further study. 
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CHAPTER 6 – THE EFFECT OF RALTEGRAVIR TREATMENT ON HIV 
INTEGRATION SITE SELECTION 
 
6.1 Abstract 
 HIV shows a preference for integration in transcription units and gene-dense 
parts of the genome.  This preference is thought to be mediated by interactions of 
viral components of the pre-integration complex with host chromatin-bound factors 
that act as integration tethers.  This has been shown with one host factor, 
LEDGF/p75, which interacts with integrase proteins of HIV and other lentiviruses, 
and whose depletion impairs integration and alters its genomic distribution.  It is 
thought that additional factors – either other tethering proteins or passive chromatin 
accessibility – also contribute to HIV integration targeting.  A recent approach to 
identifying novel host factors has been to study factors that, like LEDGF/p75, are 
necessary for efficient infection, and determining the effect of their depletion on HIV 
integration targeting.  We tested the effect on integration targeting of impairing 
infection by pharmacological means.  Cells were treated with reverse transcriptase 
inhibitors AZT or Nevirapine, or the integrase inhibitor Raltegravir.  We found that 
Raltegravir treatment altered the genomic distribution of integration sites, causing a 
shift to less gene-dense and GC-rich parts of the genome.  Other inhibitors had no 
significant effect.  These changes resemble those observed in HIV cofactor 
knockdown, leading us to speculate that a similar mechanism may be involved.  We 
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tested the idea that retargeting was related to a delay in the timing of integration, but 
found no conclusive evidence in support of this. 
6.2 Introduction 
Integration is a necessary step in the lifecycle of retroviruses such as HIV, 
enabling the virus to establish life-long infection and form a latent reservoir.  The 
integration reaction is mediated by the viral enzyme integrase (IN) [1-3].  IN mediates 
two reactions: terminal cleavage, whereby the last two nucleotides are removed from 
the end of each LTR of the reverse-transcribed genome; and strand transfer, where the 
target DNA is nicked once on each stand and the two recessed 3’ hydroxyl groups 
exposed by terminal cleavage are inserted in a concerted fashion [4-7].  HIV IN is a 
288 amino-acid protein in the RNaseH superfamily, composed of 3 structural 
domains.  The central catalytic core domain (aa 51-212) contains an RNaseH fold 
found in many DNA and RNA modifying enzymes [8, 9].  Three acidic residues, D-
DX35-E, referred to as the catalytic triad, coordinate two divalent metal ions necessary 
for catalysis [10, 11]. 
As an essential viral enzyme without a cellular counterpart, IN makes a good 
target for the development of antiretrovirals.  In 2007, the first integrase inhibitor, 
Raltegravir, developed by Merck, was approved by the FDA, and has since had great 
success in the clinic [12].  Raltegravir belongs to a class of compounds called diketo 
acids, thought to function by chelating the metal cations at the IN active site [13, 14].  
This class of inhibitors specifically inhibits strand transfer, with much weaker 
inhibition of terminal cleavage [13].  It is thought that Raltegravir binds selectively to 
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IN in complex with viral DNA, and prevents the complex from binding to target 
DNA [15].  Cytoplasmic pre-integration complexes (PICs) from diketo-acid treated 
cells showed reduced in vitro strand transfer activity, suggesting that Raltegravir may 
bind the IN-viral DNA complex before entry into the nucleus [13, 16]. 
Integration events are non-randomly distributed in the genome of the infected 
cell, with retroviruses showing genus-specific preferences for genomic features [17].  
HIV and related lentivruses show a preference for integration in active transcription 
units and relatively gene-rich regions [18].  This non-random genomic distribution is 
thought to effect optimal viral gene expression – it has been shown that 
transcriptionally silent HIV proviruses tend to show more integration in normally 
disfavored regions such as gene deserts and centromeric alphoid repeats [19].  The 
integration preferences of lentivruses such as HIV have been shown to be mediated 
by a chromatin-associated host protein, LEDGF/p75, which interacts with IN, 
tethering integration to chromatin, probably within the bodies of transcription units 
[20-22].  However, the genomic distribution of lentiviral integration sites in the 
absence of LEDGF/p75 is not fully random, suggesting other influences may also be 
important.  Suggestions of such influences have included effects of the cell cycle 
[23], additional tethering factors (discussed in Chapter 5 of this dissertation) and 
passive chromatin accessibility [24]. 
In this chapter, we present data that pharmacological inhibition of HIV 
integration by Raltegravir also alters the genomic distribution of integration sites.  
293T or Jurkat cells were treated with concentrations of Raltegravir that permitted 
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low levels of infection.  Analysis of the genomic distribution of resultant integration 
sites showed that while IN’s weak sequence specificity was not affected, integration 
sites from treated cells were found in less gene-dense and GC-rich regions.  This was 
not the case when infection was inhibited with reverse transcriptase inhibitors AZT or 
Nevirapine, nor when untreated cells were infected at a lower MOI.  While the 
mechanism of this effect remains unclear, it does not appear to result from a delay in 
integration kinetics in the presence of Raltegravir. 
These findings are provocative in our developing understanding of the factors 
shaping retroviral integration targeting, and also of the effect of this new class of 
antiretrovirals on aspects of HIV replication in treated patients. 
6.3 Materials and Methods 
Cell culture 
293T cells were cultured in Dulbecco’s Modified Eagle Medium with 
Glutamax (Invitrogen), 10% FBS (Sigma) and 50µg/ml gentamycin (Sigma).  Jurkat 
cells were cultured in RPMI (Invitrogen), 10% FBS (Sigma) and 50µg/ml gentamycin 
(Sigma). 
Virion production and infections 
 VSV-G pseudotyped HIV vector particles were produced by Lipofectamine 
transfection of 293T cells with p156RRLsin-PPTCMVGFPWPRE [25], the 
packaging construct pCMVdeltaR9 [26], and the vesicular stomatitis virus G-
producing pMD.G construct.  Viral supernatant was harvested 38 hours after 
transfection, filtered through 0.22µm filters, concentrated by filtration through a 
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Centricon, treated with DNase I, and stored frozen at -80°C.  HIV titer was quantified 
by p24 ELISA. 
 293T cells were seeded in 12-well plates, 300,000 cells per well, 6-8h before 
infection.  Jurkat cells were aliquoted into 24-well plates, 500,000 cells per well, at 
the time of infection.  For ‘high MOI’ infections, 293T cells were infected with 60ng 
p24 per well, Jurkats with 100ng p24 per well. For ‘low MOI’ infections, 300,000 
293T cells were infected with 20ng p24 per well.  The infection medium contained 
the appropriate culture medium, virus and DMSO, AZT, Nevirapine or Raltegravir at 
the concentrations stated.  Each condition was conducted in quadruplicate.  Infections 
were allowed to proceed overnight, then medium was replaced with fresh medium 
containing inhibitor or DMSO as appropriate.  Cells treated with AZT and Nevirapine 
were harvested 48h after infection.  Cells treated with Raltegravir were passaged for 2 
weeks after infection to dilute unintegrated viral genomes.  Cells treated with DMSO 
and infected at lower MOI were harvested after 48h, and cells treated with DMSO 
and infected at higher MOI were passaged for 2 weeks before harvesting. When 
passaging, inhibitor concentrations used at the time of infection were maintained. 
 For the time-course experiment, 250,000 293T cells were seeded per well of 
12-well plate, seeding 4 wells per time-point.  The following morning, cells were 
infected with 60ng p24 and 2.5ul DEAE-dextran per well.  Each condition was 
conducted in quadruplicate.  Infection was allowed to proceed for 2hr.  The 0h time-
point was harvested immediately after removal of the infection mix.  For wells 
containing longer time-points, infection mix was removed and replaced with DMEM 
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with 10% FBS and 50µg/ml gentamycin containing DMSO or 10nM Raltegravir as 
appropriate.  The same medium was left on until cells were harvested, at the time-
point stated. 
Integration site analysis 
 Integration sites were isolated and sequenced by ligation-mediated PCR 
essentially as described previously [27].  Genomic DNA was extracted from infected 
cells using the Qiagen DNeasy tissue extraction kit. Up to 2µg of DNA from each 
infection was digested overnight using MseI. This was followed by digestion to 
prevent amplification of internal viral fragments (from the 5’ LTR) and plasmid 
backbone with SacI and DpnI.  Linkers were then ligated onto digested products 
(oligonucleotide sequences listed below) and nested PCR performed from ligation 
products.  Nested PCR primers contained 8 nt barcode sequences between the 
sequencing primer and LTR-binding portions.  These enabled pooling of all PCR 
products into one sequencing reaction and subsequent separation of sequences by 
decoding the barcodes.  Samples were sequenced on the Roche 454 GS-FLX 
instrument at the University of Pennsylvania. 
 Integration sites were judged to be authentic if the sequences had a best unique 
hit when aligned to the murine (mm8 draft) using BLAT, and the alignment began 
within 3bp of the viral LTR end and had >98% sequence identity.  Detailed statistical 
methods are described in [28].  
 To control for possible biases in isolating integration sites due to restriction 
enzyme sequence distribution, three or ten matched random controls were 
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computationally generated for each experimental integration site that were the same 
distance from the closest MseI restriction site as the experimental site. 
 Integration site counts in various genomic annotations were compared with 
matched random controls by the Fisher’s exact test.  Additionally, multiple regression 
models for integration intensity were applied, as described in [28].  Analysis was 
carried out in the R statistical package (http://www.r-project.org). 
Q-PCR for integrated proviruses 
 A two-step Alu-PCR assay was used, described in reference [29].  This 
consists of an intitial round of amplification from genomic Alu repeats to viral Gag 
sequence, followed by Q-PCR specific for an amplicon in R-U5 with molecular 
beacon probes on an Applied Biosystems 7500 Fast Realtime PCR instrument.  Each 
sample was run in triplicate.  In order to standardize values across QPCR plates, 
samples were run on multiple plates as external controls.  Values for each plate were 
set to these control values. 
6.4 Results 
Isolation of HIV integration sites 
 293T or Jurkat cells were infected with a VSV-G pseudotyped GFP-encoding 
HIV vector in the presence of Raltegravir or DMSO as a control.  As additional 
controls, 293T cells were infected in the presence of AZT or Nevirapine, and 
infection with DMSO was repeated with a lower virus inoculum.  AZT- and 
Nevirapine-treated cells were harvested 48 hours after infection.  Raltegravir-treated 
cells were found to accumulate 2-LTR circles, consistent with Raltegravir function 
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[13], which contaminated integration site amplification.  These cells were therefore 
passaged for 14 days before harvesting.  The lower MOI infection was harvested 48h 
post-infection, the higher after 2 weeks of passaging.  The conditions used are shown 
in Table 6-1. 
 Integration sites were isolated and amplified from genomic DNA essentially 
as previously described [30].  The numbers of unique integration sites passing quality 
control are shown in Table 6-1.  For reference, values for computationally generated 
random sites are shown.  Random sites were generated that are matched to each 
dataset; Table 6-1 shows data from sites matched to the 293T DMSO high MOI 
dataset (see Materials and Methods for explanation). 
Consensus sequence preference at HIV integration sites is preserved in the presence 
of antiretrovirals 
 Retroviral integrases show weak consensus sequences at the site of 
integration, consisting of an inverted repeat that varies between viruses [28, 31-35].  
This consensus is a property of the integrase protein, with the symmetry of the 
inverted repeat thought to arise from IN binding as a dimer.  In the case of HIV IN, 
the consensus is TDG↓GTWACCHA, where the arrow represents the site of 
integration [32, 35].  We therefore verified that in the presence of antiretrovirals, the 
target sequence preference of IN was not affected.  Figure 6-1 shows that target site 
consensus sequences from the different treatments did not vary and were consistent 
with the published sequence.  This indicates that the integration sites isolated were 
bona fide integration events, catalyzed by HIV IN. 
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Table 6-1. Integration sets generated in this study and their genomic 
distributions.  Cells were infected under the conditions shown.  ‘Random’ is a set of 
computationally generated random sites in the genome, matched to the ‘DMSO high 
MOI’ set in terms of the distance of each site to the nearest MseI restriction site (see 
Methods for details).  Asterisks denote statistical significance by the Fisher’s exact 
test or Mann-Whitney U test as appropriate in the comparison with 293T DMSO high 
(for 293T sets) or Jurkat DMSO (for Jurkat sets). * p<0.05, ** p<0.01, ***p<0.0001. 
 
Data set
% GFP 
positive 
(FACS)
Integration 
sites
% in 
genes
Average 
number genes 
in 1Mb
Average 
GC % in 
1Mb
293T DMSO high MOI 89.6 871 72.4 20.7 43.7
293T DMSO low MOI 40.9 300 73.7 20.0 43.5
293T AZT 300nM 25.5 293 71.7 18.8 42.9
293T Nevirapine 100nM 11.5 415 71.6 22.0 44.3
293T Nevirapine 300nM 24.1 114 78.9 18.2 43.5
293T Raltegravir 10nM 31.5 316 74.7 17.4** 42.4**
293T Raltegravir 25nM 13.2 68 73.5 16.9* 42.2*
Jurkat DMSO 98.6 1890 73.8 19.6 43.5
Jukat Raltegravir 5nM 42.3 1225 75.4 15.8*** 41.7***
Jurkat Raltegravir 10nM 36.3 1218 76.0 15.2*** 41.4***
Jurkat Raltegravir 100nM 20.3 683 73.9 14.3*** 41.0***
Random 5670 35.7*** 9.95*** 40.3
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Figure 6-1. HIV integrase consensus sequence is not affected by antiretroviral 
treatment.  The 20bp sequences immediately surrounding integration sites from each 
treatment were aligned to generate a consensus using the Weblogo program 
(weblogo.berkeley.edu).  The x-axis represents the base position relative to the site of 
integration (between position -1 and 0).  The y-axis represents the bits of information 
contained at each position (the maximal value, if a position only ever had one of the 4 
bases, would be 2 bits).
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HIV integration site selection is altered by Raltegravir treatment 
 HIV integration normally favors the bodies of active transcription units, and 
regions of the genome with a high gene density [18].  We therefore started by 
examining the correlation of integration sites with these features.  Table 6-1 
summarizes the proportions of integration sites in each treatment falling within 
transcription units annotated by the RefSeq gene call.  It can be seen that, consistent 
with published data, HIV integration is roughly two-fold enriched in transcription 
units over random.  No statistically significant differences were observed between 
cell types, MOIs or antiretroviral treatments. 
 We next examined the correlation between integration frequency and gene 
density.  The average number of genes within a 1Mb window around sites from each 
treatment is shown in Table 6-1.  It can be seen that sites from cells infected at 
different MOIs did not differ in the gene density of the surrounding DNA.  Reverse 
transcriptase inhibitors AZT and Nevirapine also had no effect on the gene density 
surrounding HIV integration sites.  However, Raltegravir treatment caused a small 
but statistically significant drop in the average gene density in a 1Mb window around 
HIV integration sites, an effect which was reproduced in both 293T and Jurkat cell 
lines: in 293T cells, sites from control cells had on average 20.7 genes in the 
surrounding 1Mb, which was reduced to 17.4 an 16.9 in 10nM and 25nM Raltegravir; 
sites from Jurkat cells similarly dropped from 19.6 genes per Mb to 15.8 and 15.2 at 
5nM and 10nM respectively.  Since, based on Table 6-1, it appeared that different 
dosages of each antiretroviral showed the same trend, sites were pooled across 
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concentrations in subsequent analysis. Figure 6-2 shows pairwise comparisons of the 
correlation between integration frequency and gene density in control and drug-
treated cells.  These graphs were made by combining the two datasets to be 
compared, binning sites into 10 bins of increasing gene density with equal numbers of 
sites in each bin, and plotting the proportion of each dataset falling within that bin 
(described in detail in reference [28]).  This enables a sensitive analysis of differences 
between sets.  This analysis confirmed that the distribution of integration sites from 
cells infected at different MOIs or in the presence of RT inhibitors AZT or 
Nevirapine did not differ significantly from sites from control infections.  However, 
integration sites from Raltegravir-treated cells were more commonly found in bins of 
lower gene density than sites from control cells.  The effect was more pronounced in 
Jurkat cells, though these sets also contained more integration sites than those from 
293T cells. 
A number of genomic features correlate in the genome, for example gene-rich 
regions also tend to have short genes, short introns and be high in GC content.  We 
therefore also examined the relationship between integration frequency and GC 
content within a 1Mb window around each site.  The effects on GC content are shown 
in Table 6-1, and were similar to those for gene density.  While DMSO treatment, 
MOI and RT inhibition had no effect on the average GC content surrounding 
integration sites, regions around sites from Raltegravir-treated cells showed a small 
but statistically significant and reproducible drop in GC content (in 293Ts from 
43.7% to 42.4% or 42.2%, in Jurkats from 43.5% to 417% or 41.4%).  Sensitive 
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Figure 6-2. The effect of antiretroviral treatment on integration with respect to gene 
density.  HIV vector integration sites from cells subjected to each of the treatments shown 
were isolated and mapped onto the genome.  The number of Refseq genes in a 1Mb window 
around each site was calculated. Sites from control and treated sets were combined and split 
into ten bins of increasing gene density with equal numbers of sites in each bin.  The propor-
tion of each set found in each bin is shown. P values were determined using the likelihood 
ratio statistic for the logistic regression model.  ‘DMSO’ in 293T panels refers to high MOI 
infection of DMSO-treated cells.
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graphical pairwise comparisons between sets are shown in Figure 6-3.  A shift can be 
seen in the distribution of sites to regions of lower GC content following Raltegravir 
treatment in both cell types. 
Raltegravir does not influence the kinetics of HIV integration in the cell 
 We were surprised by the effects of Raltegravir treatment on integration site 
selection, since prevalent models of integration targeting have incorporated host 
tethering factors and variation in chromatin accessibility [24, 36], which we would 
not expect to be affected by Raltegravir.  We wondered if the observed effect could 
be explained by a kinetic effect on integration – that partial inhibition of Raltegravir 
as was performed in this experiment might act to alter the timing of successful 
integration events, and thus alter the time available for the unintegrated PIC to traffic 
through the nucleus.  It is known that chromatin folds into higher order structures in 
the nucleus, with particular genomic features clustering in particular places [37].  It 
could be imagined that the PIC might need to travel through the nucleus to its final 
site of integration, and that the time available to complete this journey could affect 
the destination reached.  We expected that Raltegravir treatment might slow the 
integration reaction, lengthening the time of PIC nuclear trafficking. 
To establish whether integration was slowed by Raltegravir treatment, we 
conducted a time-course of infection with and without Raltegravir and measured by 
quantitative PCR integrated proviral copies at intervals following infection.  293T 
cells were infected for 2 hours with VSV-G pseudotyped virus in the presence of 
10nM Raltegravir or DMSO as control.  Virus was then removed and replaced with 
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Figure 6-3. The effect of antiretroviral treatment on integration with respect to GC 
content.  HIV vector integration sites from cells subjected to each of the treatments shown 
were isolated and mapped onto the genome.  The GC content in a 1Mb window around each 
site was calculated. Sites from control and treated sets were combined and split into ten bins 
of increasing gene density with equal numbers of sites in each bin.  The proportion of each 
set found in each bin is shown. P values were determined using the likelihood ratio statistic 
for the logistic regression model.  ‘DMSO’ in 293T panels refers to high MOI infection of 
DMSO-treated cells.
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medium containing 10nM Raltegravir or DMSO as appropriate for the remainder of 
the time-course.  Cells were harvested at intervals over the next 72 hours and an Alu-
repeat-based quantitative PCR assay performed to quantify integrated proviruses.  
The results are shown in Figure 6-4.  It can be seen that starting around 6h post-
infection, the number of proviruses started to increase in both control and treated 
cells.  In both conditions, the level of integrated proviruses increased until a plateau 
was reached.  Treatment with Raltegravir reduced this plateau, as expected.  As an 
indication of the timing of integration in each condition, we calculated the time taken 
to synthesize half of the maximal quantity of proviruses for each condition (t1/2max).  
Based on this analysis, integration had reached half its maximal value at 16.9h in 
control cells and 13.9h in Raltegravir-treated cells.  Further repetitions of the 
experiment and more time-points between 12h and 24h would be required to establish 
whether there was any statistically significant difference between the two treatments, 
though these results do not suggest any large effects, and certainly provide no 
evidence for retardation of integration. 
6.5 Discussion 
 HIV integration events are distributed in the host genome with characteristic 
preferences for transcription units and gene-dense regions.  It is known that 
LEDGF/p75 contributes to this distribution, but it is possible that other factors play a 
role.  Here we present data that pharmacological inhibition of HIV integrase by 
Raltegravir leads to a redistribution of integration sites into less gene-dense and GC-
rich regions.  The changes were modest but significant and reproducible in both 
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Figure 6-4.  The effect of Raltegravir treatment on HIV integration kinetics.  293T 
cells were infected with HIV in the presence of DMSO or 10nM Raltegravir as shown.  
Cells were harvested at intervals after infection and the number of integrated proviruses 
quantified by Q-PCR.
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293Ts and Jurkats, and absent in sites from infection at a lower MOI or inhibited at 
reverse transcription.  In trying to explain this observation, we investigated one 
possible explanation – that partial inhibition with Raltegravir altered the timing of 
integration and that alterations in PIC nuclear trafficking time might affect the final 
location of integration.  A preliminary experiment did not provide strong evidence in 
favor of this hypothesis, though it suggested that in treated cells successful integration 
events, if different, take place earlier.  Further experiments with time-points at shorter 
intervals would be required to reach a definitive conclusion.  If timing were 
reproducibly altered by Raltegravir treatment, it could be interesting to analyze the 
distribution of integration sites at various times after infection to see if certain sites 
were earlier targets. 
 Another possibility is that Raltegravir induces cellular cytotoxicity, which 
leads to either changes in expression of host integration site determinants or global 
changes in chromatin structure that influence its accessibility to the PIC.  This 
possibility could be ruled out by analyzing integration sites from cells infected with 
Raltegravir-resistant virus in the presence and absence of drug, analogous to siRNA-
resistant expression commonly employed in siRNA experiments, as described in 
Chapter 5. 
 Finally, it has recently been found that type I interferons can be induced by 
cytoplasmic DNA through a TLR-independent mechanism named the Interferon-
stimulatory DNA (ISD) response [38, 39].  It has been suggested that cDNA from 
reverse transcription of retroviruses and endogenous retroelements may activate the 
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ISD response [40-42].  Perhaps inhibition of viral integration by Raltegravir and the 
resultant accumulation of viral cDNA and 2-LTR circles induces an innate immune 
response such as the ISD that leads to changes in gene expression or chromatin 
structure that affect integration site distribution.  However, whether the ISD response 
is inducible by retroviral infection in the 293T and Jurkat cell lines employed here is 
unclear [39].  A potential experiment to test this idea would be to monitor the 
expression of interferon-inducible genes in cells treated with Raltegravir.  
Additionally, cells could be treated with interferon-β and integration sites analyzed 
for recapitulation of the effects observed here.  The similarity between the effects of 
Raltegravir and the effects of siRNA treatment described in Chapter 5 are striking, 
and suggestive of some common underlying mechanism.  Perhaps induction of an 
interferon response, either in response to the accumulation of viral replication 
intermediates through the ISD, or in response to siRNA treatment, causes chromatin 
or gene expression changes that result in the effects documented here and in the 
preceding chapter. 
 The mechanism of the observations described here therefore remains unclear.  
However, it is of interest that an antiretroviral drug in clinical use appears to alter the 
genomic distribution of HIV integration sites.  An important question would be 
whether these changes have any effect on HIV replication.  Lewinski et al. [19] 
reported that the positioning of proviruses bears on their transcriptional activity: 
transcriptionally silent proviruses were more often found in gene deserts and 
centromeric repeats.  Therefore, one question would be whether the alteration of 
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integration sites by Raltegravir treatment contributes to its antiviral role by impairing 
proviral expression. 
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CHAPTER 7 – CONCLUSIONS AND FUTURE DIRECTIONS 
 
In this dissertation, I presented studies of the determinants and consequences 
of lentiviral integration in human and murine cells.  Lentiviruses have evolved to 
preferentially integrate into transcription units and gene-dense regions in the genome.  
In Chapter 2 of this dissertation, I showed that much of this preference is determined 
by an interaction between the viral integrase protein and a host chromatin-associated 
protein, LEDGF/p75.  I also reported that this preference could be modulated by 
variation in LEDGF/p75 expression within the biological range found in different cell 
types.  However, integration was still not fully random in the absence of LEDGF/p75, 
with certain preferences unaffected and new preferences emerging, suggesting other 
factors in addition to LEDGF/p75 may be involved. 
In Chapter 3 I presented data from cells expressing LEDGF/p75 fusion 
proteins with alternative chromatin-binding domains.  I reported that a LEDGF/p75 
fusion with the heterochromatin-binding protein CBX1 could retarget integration into 
normally disfavored sites: intergenic and pericentromeric regions, rich in marks of 
transcriptional repression.  This argues that, while other factors may play a role in 
targeting integration to transcriptionally active genomic regions, LEDGF/p75 
tethering appears to be central to targeting, and able to overcome potential barriers to 
integration in regions such as pericentric heterochromatin. 
Candidate factors that may contribute to lentiviral targeting in addition to 
LEDGF/p75 were investigated in Chapters 5 and 6.  These studies revealed that 
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knockdown of a number of cellular factors, or the induction of other changes to the 
cellular or nuclear environment, alter integration site selection.  The mechanism 
remains unknown, but it appears that these effects differ from the effects of 
LEDGF/p75 depletion. 
Clarifying the mechanism of the effects observed in Chapters 5 and 6 remains 
a goal of future experiments, for example by testing the idea that an innate immune 
response was elicited by the experimental conditions used.  Analyzing integration 
sites in cells knocked down both for LEDGF/p75 and for the factors described in 
Chapter 5, or treating LEDGF/p75 knockdown cells with Raltegravir as in Chapter 6, 
would also be useful.  Preliminary data from such an experiment suggest the effects 
described in Chapters 5 and 6 and the effects of LEDGF/p75 depletion described in 
Chapter 2 are indeed independent, and additive rather than epistatic (KR, data not 
shown).  Additionally, mutants of HIV that escape restriction by the host factors 
TNPO3 and RANBP2 have been selected (Vineet KewalRamani, Greg Towers, 
personal communications).  Integration site analysis with these viruses could be 
studied to test the proposed connection between the nuclear import pathway and 
integration targeting. 
One important question arising from these studies concerns the implication of 
alterations in integration targeting for viral gene expression.  It has been suggested 
that the lentiviral preference for integration in expressed genes maximizes proviral 
expression, and that integration into unfavorable genomic regions such as gene 
deserts impairs proviral expression, potentially contributing to latency [1, 2].  The 
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apparently efficient expression of vectors retargeted to heterochromatin in Chapter 3 
is therefore surprising.  In the future, epigenetic modifications of the integrated 
proviral DNA could be studied.  The expression of reporter genes from vectors 
containing different promoters could also be measured, to address the possibility of 
promoter-specific effects.  A complication in the experimental system used in Chapter 
3 is the stable expression of the CBX1-LEDGF325-530 fusion.  It is possible that this 
protein interferes with the silencing mediated by endogenous CBX1 recruitment.  The 
development of a system in which the fusion protein was only transiently expressed 
during integration, and subsequently switched off, would help test this idea – perhaps 
in the absence of the fusion protein proviral expression would be silenced as 
predicted.  Another potentially interesting experiment would be to compare the 
integration site distributions of well and poorly expressed proviruses following 
integration in the presence of the CBX1 fusion, as was performed in reference [1].  
This could enable us to ask more carefully if retargeted integration events lead to 
reduced proviral expression. 
The study of integration retargeting presented in Chapter 3 also has 
implications for the use of lentiviral vectors in gene therapy.  Previous instances of 
retroviral vector-mediated insertional activation and oncogenesis have led to concerns 
about the effect of integration in or near genes.  The retargeting presented in Chapter 
3 suggests that host integration cofactors could be manipulated to direct integration to 
parts of the genome considered to be ‘safe’. 
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Whether natural patterns of lentiviral integration are a threat to vector safety is 
an issue addressed in Chapter 4.  Here we analyzed the distribution of integration 
sites in mice treated for β-thalassemia with a lentiviral vector.  We analyzed bone 
marrow after long-term reconstitution, asking if the distribution of integration sites 
showed evidence of growth stimulation by vector integration near genes involved in 
growth control.  In contrast to a previous study in one human patient with the same 
vector (Cavazzana-Calvo et al. submitted), but in agreement with studies with other 
lentiviral vectors [3, 4], we found no evidence suggestive of insertional activation.  
However, we did observe that integration sites in cells having undergone long-term 
growth in vivo, or short-term culture ex vivo, were less frequently in transcription 
units.  This is suggestive of negative selection against cells with proviruses in genes, 
as is seen with endogenous retroviruses [5-7].  Given the natural history of HIV 
infection, it is perhaps not surprising that integration of an HIV-based vector could 
place cells at a selective disadvantage – HIV-infected lymphocytes typically live a 
short time after infection [8] so there would be little pressure for HIV to evolve a 
benign integration pattern, as is seen in the yeast Ty retrotransposons for example [9-
11]. 
Considering the findings of Chapters 3 and 4, one wonders where in the 
genome is a ‘safe’ integration site.  Further analysis of the effect of lentiviral 
integration on host gene expression is warranted.  Previous studies have shown that 
lentiviral integration can lead to both up- and down-regulation of nearby genes [12]. 
Do certain integration site distributions minimize the deregulation of host gene 
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expression?  Transcriptional profiling of cells with different integration patterns could 
be conducted.  LEDGF/p75 fusions present an attractive model in which the 
integration preference of a lentiviral vector can be modified and effects on host gene 
expression compared.  Again, the current LEDGF/p75 fusion protein system 
generated in Chapter 3 is complicated by the other modifications of the cells, but 
refining the model could enable side-by side comparison.  
The studies described in this dissertation contribute to our understanding of 
lentiviral integration, its determinants and some of its consequences.  They help 
illuminate virus-host interactions, aiding in the identification of therapeutic targets, 
and contribute to the ongoing development and evaluation of the use of lentiviral 
vectors in gene therapy. 
References 
 
1. Lewinski M, Bisgrove D, Shinn P, Chen H, Verdin E, et al. (2005) Genome-wide 
analysis of chromosomal features repressing HIV transcription. J. Virol. . 
 
2. Jordan A, Bisgrove D, Verdin E. (2003) HIV reporducibly establishes a latent 
infection after acute infection of T cells ni vitro. EMBO J. 22: 1868-1877. 
 
3. Wang GP, Levine BL, Binder GK, Berry CC, Malani N, et al. (2009) Analysis of 
lentiviral vector integration in HIV+ study subjects receiving autologous 
infusions of gene modified CD4+ T cells. Mol Ther . 
 
4. Cartier N, FAU - Hacein-Bey-Abina S, Hacein-Bey-Abina S, FAU - 
Bartholomae CC, Bartholomae CC, et al. Hematopoietic stem cell gene therapy 
with a lentiviral vector in X-linked adrenoleukodystrophy. - Science.2009 Nov 
6;326(5954):818-23. (1095-9203 (Electronic)). 
 
5. Smit AF. (1999) Interspersed repeats and other momentos of transposable 
elements in mammalian genomes. Curr Opin Genet Dev 9(6): 657-63. 
 
198
6. Lander E. (2001) Initial sequencing and analysis of the human genome. Nature 
409: 860-921. 
 
7. Brady T, Lee YN, Ronen K, Malani N, Berry CC, et al. (2009) Integration target 
site selection by a resurrected human endogenous retrovirus. Genes Dev 23(5): 
633-642. 
 
8. Wei X, Ghosh SK, Taylor ME, V J, Emini EA, et al. (1995) Viral dynamics in 
human immunodeficiency virus type 1 infection. Nature 373: 117-122. 
 
9. Boeke JD, Devine SE. (1998) Yeast retrotransposons: Finding a nice quiet 
neighborhood. Cell 93(7): 1087-9. 
 
10. Sandmeyer S. (2003) Integration by design. Proc. Natl. Acad. Sci. U S A 100: 
5586-5588. 
 
11. Xie W, Gai X, Zhu Y, Zappulla DC, Sternglanz R, et al. (2001) Targeting of the 
yeast Ty5 retrotransposon to silent chromatin is mediated by interactions 
between integrase and Sir4p. Mol Cell Biol 21(19): 6606-6614. 
 
12. Maruggi G, Porcellini S, Facchini G, Perna SK, Cattoglio C, et al. (2009) 
Transcriptional enhancers induce insertional gene deregulation independently 
from the vector type and design. Mol Ther 17(5): 851-856. 
 
 
199
enzyme 2
enzyme 1 seen unseen estimate m22=(m12.m21)/m11
seen m11 m12
unseen m21 m22
MOUSE 31
mouse 31 uncultured Nla
Mse yes no estimate m22 estimate total
yes 10 20 30 16 54
no 8 m22
18
mouse 31 methylcellulose Nla
Mse yes no
yes 0 2 no overlap, can't estimate
no 3 m22
mouse 31 all unique Nla
Mse yes no estimate m22 estimate total
yes 10 22 32 17.6 57.6
no 8 m22
18
NOTE: 3/5 sites after methylcellulose are also found before culture
MOUSE 32
mouse 32 uncultured Nla
Mse yes no estimate m22 estimate total
yes 6 12 19 20 48
no 10 m22
16
mouse 32 methylcellulose Nla
Mse yes no estimate m22 estimate total
yes 3 3 6 1 8
no 1 m22
4
mouse 32 all unique Nla
Mse yes no estimate m22 estimate total
yes 6 12 19 20 48
no 10 m22
16
NOTE: all 7 sites after methylcellulose are also found before culture
MOUSE 33.1
Supplementary Table S4-1. Capture-recapture-based total population estimates
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mouse 33.1 uncultured Nla
Mse yes no estimate m22 estimate total
yes 9 16 25 16 50
no 9 m22
18
mouse 33.1 methylcellulose Nla
Mse yes no estimate m22 estimate total
yes 4 4 8 11 30
no 11 m22
15
mouse 33.1 methylcellulose Nla
Mse yes no estimate m22 estimate total
yes 9 18 27 32 75
no 16 m22
25
MOUSE 33.2
mouse 33.2 uncultured Nla
Mse yes no estimate m22 estimate total
yes 4 8 12 26 51
no 13 m22
17
mouse 33.2 methylcellulose Nla
Mse yes no estimate m22 estimate total
yes 1 1 2 41 84
no 41 m22
42
mouse 33.2 all unique Nla
Mse yes no estimate m22 estimate total
yes 4 7 11 82.25 140.25
no 47 m22
51
MOUSE 34
mouse 34 uncultured Nla
Mse yes no estimate m22 estimate total
yes 7 21 28 12 44
no 4 m22
11
12/19 sites after MC are also found before culture
NOTE: 9/43 sites after MC are also found before culture
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mouse 34 methylcellulose Nla
Mse yes no estimate m22 estimate total
yes 4 1 5 0.75 8.75
no 3 m22
7
mouse 34 all unique Nla
Mse yes no estimate m22 estimate total
yes 7 21 28 15 48
no 5 m22
12
NOTE: 7/8 sites after MC are also found before culture
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